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ABSTRACT 
CYNTHIA JOY SNIDER: Effects of Malaria Endemicity on the Development of 
Immunity in Kenyan Children 
(Under the direction of Steve Meshnick, MD, PhD) 
 
The heterogeneity of Plasmodium falciparum (Pf-) malaria endemicity affords an 
opportunity to explore the differential effects of Pf-malaria infections on the 
development of immunity. Focusing on two areas in western Kenya with disparate 
Pf-malaria transmission intensities, this dissertation 1) examined how recurrent Pf-
malaria infections affected Epstein-Barr virus (EBV) lytic and latent antigen CD8+ T-
cell IFN-γ response among EBV co-infected infected children, and 2) described the 
differential patterns of Pf-malaria antibody responses and how they waned over 
time. We analyzed data collected over a two-year time period from children residing 
in Kisumu (high malaria transmission) and Nandi (low malaria transmission). We 
observed a 46% decrease in the prevalence of positive EBV lytic antigen IFN-γ 
response among children living in the Kisumu when compared to Nandi (PR: 0.54; 
95% CI: 0.30-0.99). Further analysis revealed impairment of EBV lytic antigen IFN-γ 
responses among 5-9 year olds. We did not identify any differences in Pf-malaria 
exposure and EBV latent antigen IFN-γ response. Results suggest there may be a 
loss of immunological control of the EBV lytic cycle among children repeatedly 
infected with Pf-malaria. Our second analysis on Pf-malaria antibody responses 
revealed that proportions of positive IgG responses to select blood-stage antigens 
(apical membrane antigens-1 3D7 and FVO strains) and the pre-erythrocytic liver 
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stage antigen-1 antigen were higher in Kisumu than Nandi (P < .05). There was a 
clear trend in the increase of IgG responses with age in Nandi but not in Kisumu 
where even the youngest age group had a high proportion of antibody responses. 
Overall, IgG responses waned over a six-month period in both districts. However the 
magnitude of the median relative change in antibody responses was generally 
greater in Nandi than Kisumu particularly among children 0-4 year olds to the 
antigens AMA-1 3D7, AMA-1 FVO, AND MSP-142 3D7 (P < .05). These findings 
indicate patterns of naturally acquired immunity evolve, and wane, differently as a 
result of heterogeneous Pf-malaria transmission intensities and age. 
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CHAPTER ONE: SPECIFIC AIMS 
 
Malaria is one of the leading causes of morbidity and mortality around the world, 
causing an estimated 225 million illnesses in 2009, resulting in approximately 
781,000 deaths.1  The global burden disproportionately affects those living in sub-
Saharan Africa where 78% of illnesses and 91% of deaths were reported.1  
Furthermore, children <5 years of age carry the highest burden of morbidity and 
mortality; globally 85% of deaths were in this age groups.1   
 Yet the morbidity and mortality estimates do not accurately convey the true 
burden of malaria because they do not take into account the consequences of co-
infections such as Pf-malaria and Epstein - Barr virus (EBV). These two pathogens 
have been implicated in the development of endemic Burkitt’s lymphoma (eBL).2  
eBL is the most common cancer among children in equatorial Africa and has been 
estimated to account for over 70% of childhood cancers in that region.3, 4  EBV 
infection has been hypothesized to be the first step in the multi-step carcinogenesis 
of eBL. EBV causes a life-long infection in B-lymphocytes.5  The second step in eBL 
carcinogenesis is believed to be recurrent Pf-malaria; however, the mechanism of its 
influence on EBV persistence is unclear. Studies have focused on establishing the 
relationship of each of these co-factors to eBL yet few studies have examined the 
interaction between these two pathogens.  
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What is clear is that the global burden of Pf-malaria infections reaches 
beyond the numbers. The incidence of malaria is decreasing in many parts of the 
world, but a need remains for an effective vaccine to supplement traditional control 
measures such as indoor residual spraying, insecticide treated bednets, and 
chemotherapy if reductions in morbidity and mortality are to be sustained.6  
Differential patterns of naturally acquired immunity exist between areas with varying 
levels of malaria transmission and this may be partially explained by the short 
lifespan of antibody responses. Studies have attempted to identify immunological 
markers of Pf-malaria infections in areas of high malaria transmission, but few 
studies have been conducted in areas of low malaria transmission.  
 We exploited the heterogeneous malaria transmission intensities of two areas 
in western Kenya to examine the issues we have raised. First, we investigated the 
role of recurrent Pf-malaria exposure on EBV-specific cellular immunity. Building 
upon cross-sectional ecological studies that have examined the effect of district-level 
Pf-malaria exposure on EBV infection, we incorporated additional time points to 
elucidate the longitudinal association of these two pathogens. We then explored the 
patterns of naturally acquired immunity in these two settings, describing the relative 
change in antibodies over time.  
 
Specific Aim 1. To assess the effect of recurrent Pf-malaria exposure on 
Epstein Barr Virus latent and lytic antigen CD8+ T-cell IFN-γ responses over 
time. 
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Hypothesis: Recurrent Pf-malaria infections deplete EBV-specific CD8+ T-cell IFN-γ 
responses.  
 
Overview: We used data collected from a cohort of children 10 months to 15 years of 
age residing in two areas of disparate malaria transmission intensities to examine 
changes in EBV-specific CD8+ T-cell lytic and latent responses over a two-year time 
period. We used a district- and individual-level definition of recurrent Pf-malaria to 
explore if malaria transmission intensity (district-level definition) is an adequate 
surrogate for individual-level Pf-malaria exposure.  
 
Specific Aim 2.  
a. To describe malaria antibody responses among children in malaria 
holoendemic and hypoendemic areas, contrasting any differences between 
the areas.  
Hypothesis: Children residing in holoendemic areas should have higher levels of 
antibodies to blood-stage antigens than children residing in hypoendemic areas. In 
addition, antibody responses to blood-stage antigens in the holoendemic area 
should show an age-trend whereas antibodies should be relatively evenly distributed 
across age groups in the hypoendemic area. 
 
b. To describe the relative change in malaria antibodies over time in malaria 
holoendemic and hypoendemic areas, highlighting any differences between 
the areas. 
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Hypothesis: Antibodies to blood-stage antigens are reportedly short-lived therefore 
antibodies should decrease over time. Yet children in holoendemic areas should 
have developed protective immunity such that the magnitude of their decrease 
should be less than children residing in malaria hypoendemic areas. 
 
Overview: We used data from a cohort of children 10 months to 15 years of age 
residing in two areas characterized by heterogeneous malaria transmission 
intensities to describe the prevalence of positive antibody responses to select blood-
stage antigens. We calculated the relative change in antibody responses over a six-
month period to characterize the change over time. 
  
   
 
 
CHAPTER TWO: BACKGROUND AND SIGNFICANCE 
 
Areas of heterogeneous malaria transmission intensity (MTI) provide a natural 
setting to investigate the influence of malaria infection on the development of 
immunity in children. The unique geographic distribution of eBL cases in high Pf-
malaria transmission areas of sub-Saharan Africa and Papua New Guinea led 
investigators to conclude that holoendemic Pf-malaria exposure played a role in the 
pathogenesis of eBL.7-9  Furthermore, differential patterns of naturally acquired 
immunity (NAI) to severe malaria between populations exposed to varying levels of 
malaria have been observed in a number of studies.10, 11  In this chapter, the role of 
Pf-malaria infection in the development of eBL and Pf-malaria humoral immunity will 
be reviewed after a general introduction to malaria.  
 
Malaria  
Malaria is a parasitic vectorborne-disease that led to approximately 225 million  
infections in 2009 resulting in an estimated 781,000 deaths, 85% of deaths in 
children < 5 years of age.1  The greatest burden of morbidity and mortality is in sub-
Saharan Africa where 78% of illnesses and 91% of deaths were reported.1  In 
Kenya, the incidence of malaria is highest among children <5 years old and is the 
most common cause of morbidity and mortality in children <2 years old.12   
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There are five species of the Plasmodium parasite that infect humans; we will 
focus on  Plasmodium  falciparum which is responsible for the majority of human 
infections, including severe manifestations such as cerebral malaria, severe anemia, 
respiratory distress, and kidney failure.13  Plasmodium parasites are restricted in 
geography to the distribution of the Anopheles vector.13  Generally, these are areas 
where the temperatures ranges from 16-33oC and the altitude is less than 2,000 
meters.14  Approximately 50% of the world’s population live in malarious areas of 
sub-Saharan Africa, Asia, Central and South America,  and the Pacific Islands 
(Figure 2.1).13, 15  Areas of high malaria transmission are found predominantly in 
sub-Saharan Africa and Southeast Asia.15 
The MTI depends on temperature, rainfall, vector, and the availability of 
infected humans. Historically, classification has been according to the proportion of 
children 2-9 years old with parasitemia or splenomegaly.14  Hypoendemic (<10%) 
and mesoendemic (11-50%) areas have seasonal or unstable malaria transmission 
whereas hyperendemic (50-75%) and holoendemic (>75%) areas have stable 
malaria transmission.14  In recent years, the use of entomological inoculations rates 
(EIR) has also been utilized to characterize MTI. Areas with an EIR < 10 have been 
used to describe areas of unstable and low transmission whereas areas with EIR > 
10 typically have high and stable transmission.16 
   
Recurrent Pf-malaria and EBV Co-infection 
It has been theorized that repeated infections with Pf-malaria adversely affects the 
immunological control of EBV persistent infection, leading to the development of  
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eBL.2  Yet the mechanism of interaction between the two pathogens remains 
unknown. To appreciate why this is, an understanding of eBL and EBV is necessary. 
Evidence linking these two diseases will be discussed as well as evidence that links 
Pf-malaria infections to eBL. Discussion about how Pf-malaria infection could affect 
EBV persistence will be followed by what is currently known about the interaction of 
the two pathogens as it relates to CD8+ T-cell response.   
 
Endemic Burkitt’s Lymphoma 
eBL  is an aggressive B-cell non-Hodgkin’s lymphoma in which tumors double in 
size within 24-48 hours.17-19  eBL is ultimately caused by a chromosomal 
translocation of the c-myc oncogene on chromosome 8 with one of the heavy or light 
immunoglobulin (Ig) chains.17, 20, 21  The c-myc proto-oncogene regulates cell 
apoptosis, differentiation and proliferation and the translocation of this gene leads to 
deregulation of vital cellular control.17, 22  Translocation is believed to be due to a 
very rare occurrence during gene rearrangement or class switching.23, 24   
eBL was first characterized in 1958 by Denis Burkitt when he published his 
observations on 32 Ugandan children between the ages of 2-14 who presented with 
a sarcoma of the jaw.20  Additional findings and reports determined eBL was 
commonly observed in equatorial Africa (referred to as “The Lymphoma Belt”) but 
not in northern or southern Africa (Figure 2.2).25-28   
eBL is the most common cancer among children in Equatorial Africa where it 
is estimated to account for over 70% of childhood cancers (Figure 2.3).17, 22  In 
Kenya alone, it accounts for 37-43% of childhood cancers.12  The incidence of eBL 
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in children <15 years in high malarious areas ranges from 5-15 per 100,000 per total 
population per year.17, 22, 25, 27, 29  eBL is commonly reported in children between the 
ages of 2-12 years with no cases reported in children <1 and few cases reported in 1 
year-old children.20, 21, 25, 30  In general, the peak age range is 4-8 years, while in 
Kenya the peak age is 6 years.8, 12, 31, 32  Males are more often diagnosed with eBL 
than females with a sex ratio ranging from 1.6-3.2 males for every female diagnosed 
with eBL.12, 25, 27, 32, 33  This observation cannot be explained as there are no 
apparent differences in admissions rates between males and females.25   
Although an aggressive cancer, eBL responds well to chemotherapy.8, 18, 26  
Chemotherapeutic drugs are able to target tumor cells effectively as a result of the 
rapid cell proliferation.26  In addition, if a portion of the tumor can be removed, either 
by surgery or chemotherapy, there is indication the patient’s own immune system 
can control and eliminate the rest.26   
The pathogenesis of eBL is hypothesized to involve EBV as the initiator and 
recurrent Pf-malaria as the promoter of EBV-infected B-lymphocyte proliferation, 
increasing the opportunity for a c-myc translocation, the hallmark of  eBL.2  Due to 
the limited geographic distribution of eBL in equatorial Africa, Burkitt initially 
suggested the cause of eBL was an “arthropod vectored-virus.”26  However, Dalldorf 
suggested in 1962 that two factors were responsible for eBL: 1) an agent found 
globally, and 2) an environmental factor such as Pf-malaria.8  It was just two years 
later when Epstein, Achong, and Barr identified a new virus in electron micrographs 
taken of cultured eBL cells, later named the Epstein-Barr Virus (EBV).34  In 1982, 
Klein synthesized contemporary research into a cohesive explanation of the three 
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stages of eBL evolution that still prevails today.2  The first stage entails primary EBV 
infection; dé The and colleagues identified that pre-eBL children had significantly 
higher antibody titers to the EBV viral capsid antigen (VCA) than matched controls.2, 
27  Immunological modulation by recurrent Pf-malaria exposure is the second step in 
the process. Pf-malaria has been proposed to impair EBV-specific T-cell immunity19, 
35 and/or lead to proliferation of EBV-infected B-lymphocytes.2, 19  This impairment 
and proliferation increases the probability of the occurrence of a c-myc translocation 
which leads to stage 3, the development of eBL.2, 19, 22   
Studies of eBL etiology that directly examine the relationship between 
recurrent Pf-malaria and EBV are challenging. The relatively low incidence of eBL 
cases, 5-15 per 100,000 per total population per year depending on location, makes 
longitudinal cohort studies of eBL difficult to conduct.17, 22, 25, 27, 29  A prospective 
seroepidemiological study was conducted over a two year span collecting samples 
from 42,000 children less than 9 years old, of which only 14 eBL cases  were 
available for inclusion in analyses.27  Furthermore, establishing temporality of 
exposure-outcome is an important concern for eBL case-control studies because 
there is no clearly established biomarker for the development of eBL. Likewise, there 
is no clear biomarker for the accumulation of repeated Pf-malaria infections.  
Furthermore, it is possible that EBV biomarkers (e.g., antibody titers, EBV load) 
assessed as exposures may in fact be the result of eBL disease (i.e., reverse 
causality).33   
The only two studies assessing the joint effects of Pf-malaria and EBV among 
eBL cases showed an important interaction.33, 36  Both case-control studies found the 
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odds of high antibody levels to both EBV and Pf-malaria in eBL cases to be 
significantly higher than controls with low antibody levels to both EBV and Pf-
malaria.33, 36  In one study, the odds ratio (OR) for the joint effect was 13.2 (95% 
confidence interval [CI]: 3.8-46.6) while the OR for Pf-malaria alone was 1.4 (95% 
CI: 0.3-6.3) and EBV alone was 5.7 (95% CI: 1.6-20.7).36  In the other study, the OR 
for the joint effect of EBV and Pf-malaria was 5.0 (95% CI: 2.8-8.9) while the OR for 
Pf-malaria alone was 1.1 (95% CI: 0.5-2.4) and EBV alone was 1.0 (95% CI: 0.5-
2.2).33  Although OR estimates are imprecise, the magnitude of association and the 
synergistic effect indicates that the interaction of the two pathogens play an 
important role in the pathogenesis of eBL.   
There is an important interaction between recurrent Pf-malaria and EBV yet 
the mechanism behind the interaction is not well understood.   In the absence of eBL 
longitudinal studies that could focus on the interplay between recurrent Pf-malaria 
and EBV, other types of studies can provide insights.    
 
Epstein-Barr Virus 
Epidemiology of EBV 
EBV is a ubiquitous virus that is transmitted orally through saliva.5, 13  Over 90% of 
adults carry antibodies to EBV and young children often contract the virus from 
sharing toys and consuming foods pre-chewed by parents.3, 5, 13, 37  EBV is shed 
continuously in the saliva of healthy EBV seropositive individuals although very few 
viruses are infectious.38   
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In developing countries, 99% of primary infections occur in children by the 
age of 3 years.22, 39  Maternal antibodies to EBV offers protection in young infants 
until 5-7 months.39  Infection in young children is asymptomatic and serological 
testing is often the only evidence of past infection.40-42  In contrast, the age of 
primary infection in developed countries is delayed until adolescence or young 
adulthood of which 35-50% presents as symptomatic infectious mononucleosis.5, 39, 
43  The difference in age of primary infection is attributed to improved living 
conditions and hygiene in developed countries. 41, 44  There has been some evidence 
that females have higher anti-VCA immunoglobulin (IgG) titers than males, although 
there does not appear to be any difference in the age of primary infection by sex.45, 
46  
 
Infection, Persistence, and Immune Response 
EBV is a double stranded DNA virus of the gamma herpes family that is B-
lymphotrophic.41  The location of viral replication is still debated but evidence 
suggests EBV infects epithelium cells and naïve B-lymphocytes of the 
oropharyngeal epithelium.5, 19, 38, 47, 48  Similar to other herpes viruses, EBV has two 
life cycles: lytic (productive) and latent (non-productive).41, 49  During lytic infection, 
the virus replicates within the epithelial cells and naïve B-lymphocytes, leading to 
cell death when virions are released.41  The control of EBV proliferation during this 
phase is brought about by T-cell response, especially cytotoxic CD8+ T-lymphocytes 
(CTL).50   
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EBV causes a life-long latent infection in resting memory B-lymphocytes.5, 19  
A proportion of EBV-infected naïve B-lymphocytes escape the host’s immune 
system by migrating to lymph nodes where they pass through the follicle to form 
germinal center reactions, colonizing the resting memory B-lymphocyte pool.5, 19, 47  
These EBV-infected memory B-lymphocytes contain viral genetic material but do not 
produce virions.5  Latently infected memory B-lymphocytes are capable of polyclonal 
proliferation or activation to the lytic cycle.41, 48  This latter shift occurs when latently-
infected memory B-lymphocytes differentiate into plasma cells.47, 51   
EBV primary infection leads to a strong T cell-mediated response which also 
dominates immunosurveillance and control of EBV latency.22, 35, 50, 52  Natural killer 
cells of the innate immune system are the first to respond during primary infection. 22  
This is quickly followed by CTL response which targets both lytic and latent viral 
proteins.19, 35, 50  In healthy EBV seropositive individuals, EBV-specific memory CTL 
cells represent up to 5% of all circulating CTL cells, indicating the pivotal role of T-
cell immunosurveillance in controlling EBV latent infection.19, 22, 50  EBV is a powerful 
B-lymphocyte mitogen that leads to continued proliferation in vivo and transformation 
to immortalized lymphoblastoid cell lines (LCL) in vitro.22, 42, 50, 53, 54  Failure to control 
latent infection leads to uncontrolled proliferation of EBV-infected B lymphocytes.22   
EBV-infected B-lymphocytes evade T-cell immunosurveillance through a 
number of mechanisms:  down-regulating expression of almost 100 viral genes to 
just 12 thereby rendering it non-immunogenic, reducing the expression of major 
histocompatibility complex (MHC) class I receptors on the cell surface to prevent 
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CTL recognition, producing viral cytokines that enhance B-lymphocyte infectivity and 
counteract immune response, and inhibiting apoptosis.17, 37, 55-57   
  After primary infection, EBV load is dependent on immunosurveillance of 
latent EBV infection. EBV load in healthy seropositive individuals is stable over time 
with 1-50 latently infected cells per million circulating B-lymphocytes.55, 58  Increases 
in EBV loads may be a consequence of reduced T-cell control, as observed in post-
transplantation patients and AIDS cases.49, 59  However no point prevalence 
correlation has been observed between EBV loads and EBV-specific CD8+ T-cell 
IFN-γ response.35  In addition, EBV DNA detected in plasma and serum is a 
combination of encapsidated and naked DNA, signifying active EBV replication and 
apoptosis, respectively.48, 58, 60  Individuals with a mixture of encapsidated and naked 
EBV DNA have the highest EBV loads.58   
Maintenance of EBV persistence is not well understood but is believed to be a 
balance between latent infection, replication (i.e., lytic phase), and the immune 
response.48, 57, 59, 61  EBV-infected resting memory B-lymphocytes are a reservoir for 
persistent infection and the shift from latent infection to replication occurs when a 
portion of these latently-infected lymphocytes differentiate into plasma cells.51, 56  
The signal that triggers plasma cell differentiation is unknown.56  EBV replication 
leads to viral shedding in the saliva and infection of naïve B-lymphocytes that 
migrate to the lymph nodes where they seed additional pools of uninfected resting 
memory B-lymphocytes.48, 56  Replication elicits an immune response which once 
again brings the virus under control.56, 57   
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Relationship between EBV and eBL 
EBV is a necessary but not a sufficient cause of eBL.24  It is recognized that 
chromosomal translocation of the c-myc oncogene initiates the development of eBL, 
yet there is evidence to suggest EBV has an active role in its pathogenesis.  First, 
EBV was discovered in electron micrographs of cultured eBL cells.34  Subsequent 
tumor studies found approximately 97-98% of eBL tumors were positive for EBV. 2, 
22, 50, 62  Second, eBL tumors develop from a cell (or cells) already infected with EBV, 
suggesting EBV infection occurs in the early stages of the pathogenesis of eBL 
rather than after tumor development.24, 63  Third, individuals diagnosed with eBL had 
high anti-VCA titers prior to development of eBL.41, 44, 64, 65  As anti-VCA titers are 
stable over time, the high titers before and after eBL onset may indicate suppression 
of EBV-specific T-cell immunity. Fourth, EBV leads to the transformation of normal 
B-lymphocytes to immortalized LCL in vitro; in vivo, EBV leads to proliferation of 
EBV-infected B-lymphocytes.22, 42, 50, 53, 54  This proliferation increases the risk for 
eBL to emerge. Finally, EBV is linked to other cancers, such as nasopharyngeal 
carcinoma, and has demonstrated neoplastic growth in immunocompromised 
individuals suffering from B-lymphocyte lymphoproliferative disease.24, 27   
 
Pf-malaria and EBV Co-infection 
Chronic Pf-malaria is immune-modulating.26  Studies of acute Pf-malaria infection 
during vaccination programs have found that Pf-malaria alters the capacity of 
children’s immune systems to mount a response.66-68  Immune competence rapidly 
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returns with parasite clearance indicating children with asymptomatic infection may 
still experience a degree of modulated immune response.22, 67-71   
Malaria is a powerful B-lymphocyte mitogen.  In vitro, the cysteine-rich 
interdomain region 1α  (CIDR1α) domain of  the P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) is able to activate proliferation of B-lymphocytes from 
individuals with no previous malaria exposure.72  It targets activation of memory B-
lymphocytes and also provides protection against apoptosis.73  A recent study 
demonstrated a direct link between CIDRα and EBV infected B-lymphocytes 
suggesting CIDRα could trigger reactivation of EBV-infected B-lymphocytes during 
acute malaria infection.61  In areas of high malaria transmission, asymptomatic 
parasitemia may result in persistent proliferation of memory B-lymphocytes.73  
 
Relationship between Pf-malaria and eBL 
Pf-malaria is a cofactor in the pathogenesis of eBL (necessary but not sufficient). It 
is not Pf-malaria infection itself that is believed to be a cofactor but rather the 
prolonged exposure to Pf-malaria infection results in elevated risk of eBL 
development.2, 29, 31, 32  The highest incidence of eBL has been identified in malaria 
holoendemic areas where early investigations noted the similarity in the 
geographical distribution of eBL and holoendemic malaria in equatorial Africa and 
Papua New Guinea.26, 27, 30  For example, of the 1,005 eBL cases identified from 
1988-1997 in Kenya, only 7% were from malaria free areas.12  In addition, the 
introduction of antimalarials in areas of high malaria transmission led to a decrease 
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in the number of eBL cases thereby suggesting a link.7, 32  Furthermore in 
holoendemic areas where control programs were instituted, eBL is rarely detected.7   
The coincidence of Pf-malaria infection and eBL suggests a temporal 
relationship. Symptomatic Pf-malaria peaks in children aged 2-3 years while eBL 
peaks in 4-8 years.74  Two additional interesting observations are noted in Burkitt’s 
work in Uganda. First, the average  age of eBL patients in malarious areas was 8.1 
years, while in low risk malarious areas it was 16.2 years.25  In addition, immigrants 
from unstable  malaria transmission areas of Uganda who moved to holoendemic 
areas presented with eBL in late adolescents and adulthood, almost 50% over the 
age of 15.25  Morrow’s work also found a similar pattern as most adult cases of eBL 
that he identified were born in hypoendemic areas.32   
Furthermore, there is also evidence that children with sickle cell trait (HbAS), 
which protects from severe Pf-malaria infections,  have lower incidence of eBL than 
children without the trait (HbAA).75  Finally, eBL cells appear to have their origin in 
germinal-cells and chronic Pf-malaria infection induces germinal center 
hyperactivity.22, 24, 63  Viral reactivation coupled with expanded germinal centers 
increases the risk for a random mutation to occur in an EBV-infected germinal center 
lymphocyte.24, 63   
 
Current Knowledge of the Effect of Recurrent Pf-malaria Infections on EBV 
Infection  
This section focuses on current understanding of recurrent Pf-malaria infection and 
EBV T-cell response. A summary of studies can be found in Table 2.1. 
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An important criterion in establishing disease causality is that exposure 
occurs before disease. Recalling the chronology of the three stages of eBL 
progression – EBV infection, recurrent Pf-malaria, and eBL (i.e., c-myc translocation) 
– it is clear that there is the potential for chronic Pf-malaria to affect EBV latent 
infection, giving rise to eBL (Figure 2.4). As previously noted, 99% of primary EBV 
infections occur in children by the age of 3 years in developing countries.22, 39  In 
holoendemic areas, symptomatic Pf-malaria infections peak in children aged 2-3 
years, although infections continue into the teen years.74  This would indicate 
children are already EBV seropositive when they experience repeated Pf-malaria 
infections in their early childhood. Recall that eBL peaks in children 4-8 years, soon 
after the peak age-related incidence for Pf-malaria infection.74   
There are two prevailing, though not mutually exclusive, theories on the role 
of recurrent Pf-malaria on EBV infection and immunity. The first hypothesizes 
impaired EBV-specific T-cell immunity.19  EBV-specific T-cell immunity is responsible 
for immunosurveillance and control of EBV latent and lytic proteins; however, 
chronic Pf-malaria may impair EBV-specific T-cell immunity, resulting in inadequate 
immunosurveillance of EBV. 19, 35  The second theory hypothesizes that EBV-
infected B-lymphocytes proliferate as an individual is repeatedly exposed to Pf-
malaria.19  The increased number of EBV-infected B-lymphocytes thereby increases 
the risk for the emergence of an EBV-infected B-lymphocyte with the malignant 
mutation, leading to the development of eBL.19   
Acute Pf-malaria infection leads to impaired T-cell control of persistent EBV 
infection. Studies comparing children’s T-cell response during and 3-4 weeks after 
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Pf-malaria infection found a significant increase in the number of EBV-infected B-
lymphocytes and high regression indices, both supporting the conclusion of a loss of 
CTL function.76-78  By nature of these studies, it is clear that acute Pf-malaria 
infections have a transient effect on T-cell response. Furthermore, findings from 
case-control studies comparing acutely infected Pf-malaria individuals with healthy 
adults came to the same conclusion.69, 79   
The cumulative effect of Pf-malaria infections on T-cell control of persistent 
EBV infection has not been well researched. Two ecological studies comparing 
holoendemic areas to areas of unstable malaria transmission have been conducted 
yielding different conclusions. One study found a significant difference in T-cell 
function between the two areas, with individuals living in holoendemic areas showing 
a loss of T-cell response.80  However this study was conducted among adults who 
have mature immune systems as compared to children. A more recent study among 
children found no overall difference between the two areas; however, among 
children residing in the holoendemic area, a significant decrease in T-cell response 
was observed in children 5-9 years old compared to other age groups.35 Although 
using malaria transmission as a surrogate for cumulative Pf-malaria infections is not 
ideal, these findings provide the only understanding we currently have on the 
cumulative effect of Pf-malaria exposure on latent EBV infection. 
 
Naturally Acquired Immunity to Pf-malaria Infection 
Unlike other infectious diseases, such as measles, life-long protective immunity (i.e., 
sterilizing immunity) never develops to Pf-malaria and individuals remain vulnerable 
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to re-infection throughout life.16, 81  Yet partial immunity is developed over time 
whereby individuals progress from symptomatic illness with high parasite densities 
to asymptomatic illness and low density parasitemia.16   
To understand the complex weave of interactions between the parasite and 
immunity in the human host, an understanding of the parasite life cycle and the 
critical role of humoral immunity is necessary. This will set the foundation for the 
description of how NAI evolves and how the longevity of antibodies affects NAI. 
Finally, we will review how NAI is influenced by heterogeneous patterns of 
transmission and age and the implications this has for protection from symptomatic, 
or clinical, disease.  
  
Life Cycle of Pf-malaria 
Pf-malaria parasites require two hosts as part of their life cycle, female Anopheles 
mosquitoes and humans, but our focus will be on the lifecycle in the human host 
(Figure 2.5).82, 83  When an infected female mosquito bites a human host, she 
releases parasites called sporozoites into the bloodstream where they rapidly invade 
hepatocytes, or liver cells.82, 83  These parasites mature in liver cells during this pre-
erythrocytic, or liver stage.82, 83  Upon rupture, merozoites (extracellular form of the 
parasite) are released and invade erythrocytes, or red blood cells (RBCs). Invasion 
of the RBC begins with a reversible attachment between the merozoite and RBC 
(Figure 2.6).82, 84, 85  The merozoite then reorients its apical end to bring it in contact 
with the RBC where an irreversible, tight attachment is formed.82, 84, 85  It enters the 
RBC surrounded by a protective vacuole that seals once the merozoite is fully 
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integrated into the RBC82, 85 where they undergo asexual replication (referred to as 
erythrocytic or blood stage).83  Most parasites in the blood stage continue in asexual 
replication, infecting more RBCs when merozoites are released.82, 83  A small 
proportion of parasites do not return to asexual replication but enter the sexual stage 
where they differentiate into male or female gametocytes.82, 83  Gametocytes are 
ingested by mosquitoes to continue their lifecycle in mosquitos.83, 86   
Symptomatic infection in the human host is restricted to the asexual blood-
stage when merozoites replicate in RBCs and are released into the bloodstream.86, 
87  This release of merozoites leads to inflammatory responses that cause the 
hallmark malaria symptoms of fever, rigor, and nausea.86, 87  Parasites of the liver 
stage and gametocytes do not cause symptomatic illness and this has been 
hypothesized to be due to their poor immunogenic capacity.6  
 
Humoral Immunity to Pf-malaria Infection 
Studies in the early 1960’s demonstrated that gamma globulin from healthy 
malaria-immune adults were effective in reducing the parasite density and clinical 
symptoms of malaria in children hospitalized with malaria.88-90  These studies 
established the critical role of antibodies to blood-stage antigens as a significant 
component in NAI to malaria infections. The mechanisms by which antibodies can 
control Pf-malaria infection include direct elimination of parasites, prevention of 
merozoite invasion of RBCs, and aiding in the detection and clearance of infected 
RBCs.82, 91-93   
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Blood-stage antigens of particular interest are the apical membrane antigen 
(AMA)-1 and merozoite surface protein (MSP)-1 and both have been the focus of 
vaccine development. AMA-1 is a highly polymorphic antigen82 and is highly 
immunogenic.94, 95  Antibodies to AMA-1 antibodies have been shown to prevent 
reorientation of the merozoite on its apical end thereby preventing the critical 
attachment necessary for invasion.85  Recently, AMA-1 was also found to be 
expressed by sporozoites of the pre-erythrocytic stage. Once again, AMA-1 appears 
to play a vital role in cell invasion because antibodies to AMA-1 prevented invasion 
of hepatocytes.96  Like AMA-1, MSP-1 is a highly polymorphic antigen but it is not as 
immunogenic as AMA-1.95 97  MSP-1 coats the surface of merozoites but its precise 
function of remains unknown.84  It is processed into a number of fragments including 
MSP-142. and during invasion of the RBC, MSP-142. is further processed into MSP-
119 and MSP-133.91  Antibodies to MSP-1 have been shown to prevent merozoite 
invasion of RBCs.82, 98  In addition, animal studies demonstrated that antibodies to 
MSP-1 protected primates from infection.97  
Sporozoites of the pre-erythrocytic stage are reportedly poorly immunogenic 
because they have less antigenic polymorphisms, indicating less pressure from the 
host’s immune system.6  Yet antibodies to sporozoites have been detected 
suggesting a potentially contributory role in NAI.6  The suggested mechanisms of 
protection are similar to those proposed for blood stage antibodies - direct 
elimination of sporozoites, prevention of sporozoite invasion of hepatocytes, and 
clearance of infected hepatocytes.93  Levels of pre-erythrocytic antibodies, such as 
the liver stage antigen (LSA)-1, have been reported to appear only after many years 
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of Pf-malaria exposure,6, 93  although one study reported LSA-1 IgG levels in 
infants.99  However, IgG responses in children are reportedly lower than adults.100  
Even though IgG responses to pre-erythrocytic antigens have been observed to be 
consistently lower than levels of blood-stage antibodies,6, 93  comparisons between 
Pf-malaria immune and naïve individuals suggest that antibodies confer a degree of 
immunity against parasites.6  Furthermore, significantly higher levels of LSA-1 
antibodies were detected in high malaria transmission areas as compared to low 
areas indicating they may be involved in some level of protection.101  
 
Evolution of NAI 
Susceptibility to malaria is universal barring specific genetic traits that offer 
partial resistance to Pf-malaria infection.13, 87  Individuals with heterozygous sickle 
cell trait (HbAS) have partial resistance to Pf-malaria, leading to reduced parasite 
density and lower risks for severe forms of malaria whereas individuals homozygous 
for the trait (HbSS) appear to be at greater risk for severe disease.13, 87  Glucose-6-
phosphate dehydrogenase deficiency is another genetic trait that protects individuals 
from severe manifestations of Pf-malaria infection.102  
The development of NAI is a complex process that occurs between the Pf-
malaria parasites and human host. Parasites incorporate various techniques to 
evade, and even suppress, the human host’s immune response. The life cycle of 
parasites encompasses a diverse array of expressed antigens. Furthermore, 
parasites have developed polymorphic regions on antigens believed to be the result 
of frequent targeting by the host’s immune response.6, 82, 91, 93, 103  Allelic 
   
 23
polymorphisms have led to different genotypes, or strains, within a single species, 
such as 3D7 and FVO.16  The predilection of parasites for liver and RBCs with 
limited or no major histocompatibility complex molecules means an efficient T-cell 
response cannot be mounted.6, 82, 92  Immune suppression strategies include 
malaria-specific B- and T-cell apoptosis (cell-death) and the prevention of dendritic 
cells from maturing thereby preventing antigen recognition and presentation to T-
cells.6, 103, 104   
In this web of interactions with parasites, humans have evolved a complex 
immune response that manages to transform symptomatic illness to asymptomatic 
control of parasite density.16  This response has been described in three phases 
(Figure 2.7). During the first phase, immunity to severe, life threatening infections is 
acquired after just a few infections despite an increasing prevalence of parasites.81, 
93, 105  The next phase brings about clinical, or anti-disease, immunity whereby 
individuals no longer suffer from symptomatic illness in spite of relatively high 
parasite densities.16, 81  Acquisition of partial immunity to parasite immunity (anti-
parasite) is the final phase, where parasitemia density remains low throughout 
infection.16, 81   
The mechanisms responsible for this slow evolution of immunity are not well 
understood and should not be assumed to be similar for all phases.93  It has been 
reasoned that maturation of immunity requires years in order to be exposed to 
variants of each antigen, although there is evidence of partial immunity to 
heterologous strains in the form of lower parasite densities and shortened courses of 
symptomatic illness.16, 93  Symptomatic illness has been purported to be the result of 
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an individual being exposed to a novel variant in which there was no prior 
exposure.6, 106  As individuals experience repeated Pf-malaria infections, they 
accumulate a sufficient antibody repertoire such that they no longer suffer from 
symptomatic illness but continue to carry parasites.16, 93  Described in the 1900’s by 
Koch as “premunition,” low levels of parasites was believed to be necessary for 
maintaining immunity; interruption led to a loss in immune response.16, 81   
 
Longevity of Antibodies 
The loss of immunity has been attributed to the short lifespan of serum 
antibodies to Pf-malaria antigens107, 108 but this may not be universal nor this simple. 
Naïve B-cells that encounter merozoites differentiate into short-lived plasma cells 
(SLPCs), secreting over 5,000 IgG molecules per second.109 SLPCs have been 
estimated to survive between 8 hours to as long as 10 days.109  Meanwhile some 
naïve B-cells make their way into germinal centers of follicles in the lymph nodes 
where they develop into high affinity antibodies, either differentiated B-cells called 
long-lived plasma cells (LLPCs) or memory B-cells (MBCs).109-112 An estimated 80-
90% of LLPCs are sequestered in the bone marrow where they continuously secrete 
antibodies, maintaining serum antibody levels even in the absence of infection; their 
lifespan in humans is unknown.109-113  SLPCs and LLPCs are vital for the initial 
control in infection.109-111  MBCs are critical for rapid secondary responses, having a 
low threshold for activation but peaking 6-8 days after re-exposure to their cognate 
antigen.109, 111   
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A hallmark of the immune response is the ability to recognize antigens that 
have already encountered. A lack of recognition therefore implies an absence of 
memory. The immune response to Pf-malaria infections suggests an absence of 
memory because people become repeatedly infected and ill. Therefore attempts 
have been made to delineate the contribution of LLPCs and MBCs to serum 
antibody levels but conclusions have been conflicting.92  One study concluded there 
was a defect in MBCs to specific Pf-malaria antigens,98 but another study reported 
slow and steady acquisition of MBCs to the same Pf-malaria antigens investigated in 
the first study.111  Once again, the hurdle in developing long-term memory may be 
the challenges created by the Pf-malaria parasite whereby appropriate, high affinity 
antibody responses cannot be developed due to an ever changing repertoire of 
antigens on the merozoites.109, 111  Although the activation of MBCs is typically 
antigen-dependent, there is evidence of antigen-independent activation (referred to 
as bystander activation) of Pf-malaria-specific MBCs antibodies.109-111, 114   
Evidence arguing for the short lifespan of serum antibodies is numerous.  
First, high levels of antibody responses have been associated with parasitemia,97, 98, 
109, 115, 116 but antibody responses declined after symptomatic infection ceased97 or 
once effective treatment commenced.6, 97  In areas that experience seasonal 
transmission of Pf-malaria, studies have found that antibodies wane over time from 
the high to low season.6, 100, 107, 117, 118  Furthermore, a commonly cited situation is 
when adults return to malaria endemic areas and suffer from symptomatic infection 
despite repeated Pf-malaria infection during their childhood.92  Studies have reported 
that antibody responses to MSP-1 and other antigens are short-lived in infants119, 120 
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and children compared to adults.92, 109, 117  Yet these differences may be due to the 
maturity of immune systems in adults compared to infants and children. 
Studies that have estimated the half-lives of antibodies have been limited and 
inconsistent. IgG1 responses were reported to have a half-life of 21 days.108 
However, another study that examined IgG1 responses specific to Pf-malaria IgG 
responses (combination of blood-stage antigens including MSP-1 and AMA-1) 
reported IgG1 responses had a half-life of 10 days.107 Still another study determined 
the half-life of MSP-119 responses was 49 years.94  The contradictory findings may 
be attributed to different antigens tested but nevertheless, the half-life of antibodies 
remains an open area for research and discussion. 
What is likely a more accurate description about the longevity of antibody 
responses is that there is a careful and coordinated balance between both short- 
and long-lived responses whereby clinical immunity develops rather than parasite 
immunity.109 The short life-span of antibodies is not indicative of a lack of 
immunological memory especially because rapid proliferation of antibody responses 
have been observed after exposure.6  In addition, regardless of the MTI, only a few 
Pf-malaria infections may be necessary to protect from severe,  non-cerebral 
malaria.105  Reexamining the example of adults returning to malaria endemic areas, 
what is often overlooked is that their course of illness is often shorter in duration and 
their risk of severe forms are less than immune naïve individuals.6  For example, in 
Madagascar after the unraveling of intense malaria control efforts from previous 
decades, a 1987 malaria outbreak left young adults and children with high 
proportions of symptomatic illness whereas older adults who were exposed to 
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repeated Pf-malaria infections as children suffered from less disease.121  Hence 
antibodies do persist in the absence of antigens that stimulate an immune 
response.109   
 
Malaria Transmission Intensity and Age Effect on the Evolution of Immunity 
The patterns of NAI in individuals vary by malaria transmission intensity and 
age with the exception of infection in infants. Maternal antibodies appear to provide 
protection among infants from fever, high density parasitemia, and severe illness 
until they are about 6 months old when protection begins to wane.16, 87, 99, 102, 122, 123  
In areas of stable and high malaria transmission, symptomatic Pf-malaria 
infection, including severe forms, disproportionately affect children < 3 years old with 
monthly parasite prevalence among this age group reported to be as high as 90%.10, 
11, 87, 119, 122-125  At 6 months of age, infants become susceptible to infection.16, 87, 102, 
122, 123  Parasite densities were observed to peak in infants 6-11 months followed by 
a rapid decline with age.122, 126  There is a subsequent decline in symptomatic illness 
and eventual decrease in parasite density with age, which is attributed to the 
accumulation of antibodies in response to repeated infection.10, 122  This same 
pattern of acquired immunity is also observed for adults who move from low to high 
malaria endemicity areas.10, 16   
Immunity in individuals residing in areas of low malaria transmission is not 
well as developed as demonstrated by the burden of symptomatic Pf-malaria 
infections being distributed across all age ranges while severe Pf-malaria infections 
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typically is reported in 1-5 year olds.10, 11, 14, 16, 123, 125, 126  High febrile illnesses 
among all ages have been reported during periodic outbreaks.6   
Studies of antibody responses have generally found IgG responses to AMA-
1,94, 95, 101 MSP-119,94, 95, 101, 127, 128 and LSA-1 94, 101, 129 to be greater in high 
transmission areas as compared to low areas. In high transmission areas, they have 
also shown that the prevalence of AMA-195, 101, 119, 130 including AMA-1 FVO131, MSP-
11995, 120, 128, 132, 133, MSP-142130, and LSA-199-101, 119 antibodies increase with age but 
not always for MSP-119134, 135 or  LSA-1130, 136. Limited studies have been conducted 
in areas of low malaria transmission and these have found that AMA-195, 101 and 
MSP-119 95, 101, 128 increased with age but not consistently for AMA-1 FVO131 or MSP-
119.134, 137 LSA-1 responses were significantly higher in adults in one study118 but 
another study detected no age trend.101 An interesting observation was that 
symptomatic illness was not found to be correlated with parasite density in areas of 
high malaria transmission whereas in areas of low transmission, there was a clear 
correlation.16  
There is evidence that age may be independently related to the NAI although 
teasing out its independent effect in areas of high malaria transmission has been 
problematic. Adults who move into high malaria transmission areas suffer from 
symptomatic illness yet they develop the ability to prevent fever and control 
parasitemia faster than children.16  Furthermore, adults are at greater risk for severe 
illness as compared to children as MTI declines.16, 138  The risk of cerebral malaria is 
low in all children < 5 years old regardless of MTI, but in areas of low- or moderate-
transmission, there is a J-shaped association with increasing age, whereas in areas 
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of high transmission, risk of cerebral malaria remains low.138  The initial decrease in 
the J-shape was hypothesized to be due to the acquisition of immunity to severe 
malaria among young infants.105, 138   
   
Evidence of Clinical Protection from Pf-malaria Infection 
Efforts have been underway to develop of an effective vaccine for Pf-malaria 
infection. There is growing evidence that a multivalent vaccine that can elicit an 
immune response to a number of antigens will be necessary.82, 93, 103, 119  As 
previously mentioned, the vaccine will have to overcome the vast array of evasive 
strategies utilized by parasites. To compound this problem, a further challenge has 
been identifying antibodies that are immunological markers of protection.92  Few 
studies have examined the protective effect of antibodies to multiple antigens.136, 139 
What complicates research further is that less than <1% of known antigens have 
been studied thus far.92  Prioritizing antigens for investigation has been hindered by 
the lack of knowledge on the precise function of a majority of the known antigens.82  
Finally, most studies have been conducted in areas of stable malaria transmission 
but patterns of NAI vary across MTI. Therefore it is unclear if the mechanism driving 
NAI in these areas are relevant to individuals infrequently exposed to Pf-malaria.  
 Studies of protection from symptomatic Pf-malaria infection in sub-Saharan 
Africa have generally found little evidence of protection associated with AMA-1. Only 
one study found that AMA-1 antibodies were protective140  and another determined a 
combination of AMA-1 and MSP-2 antibodies reduced the risk of symptomatic Pf-
malaria infection.141  Still the majority of studies indicated no association.127, 132, 136, 
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142  Evidence of a protective effect of MSP-119 antibodies is inconsistent. Although 
positive associations have been detected127, 128, 133, 137, 141 there have also been 
reports of no association.132, 134, 135, 140, 142 Limited studies on 3D7 and FVO strains 
have generally suggested antibodies to AMA-1 3D7,130, 131 AMA-1 FVO131, and MSP-
1 3D7130 are protective of symptomatic Pf-malaria infection, but antibodies to MSP-1 
FVO are not.130 Finally, the MSP-119  block 2 has been linked with protection from 
symptomatic illness.143-145 
A recent meta-analysis of population-based longitudinal studies generally 
corroborated these findings between AMA-1 and MSP-1 and protection from 
symptomatic Pf-malaria infection.91  Antibodies to the 3D7 strain of AMA-1 reduced 
the risk of symptomatic illness whereas results for the FVO strain of AMA-1 were not 
as conclusive.91  Antibodies to MSP-119 led to an 18% decrease in the risk of 
symptomatic illness among individuals with detectable IgG responses as compared 
to non-responders.91  Further analysis revealed that there was a 15% decline in the 
risk of symptomatic illness for every doubling of antibody responses (log base 2).91  
Studies of MSP-142 were not reported.  
LSA-1 antibodies independent of other pre-erythrocytic antigens does not 
appear to confer clinical immunity.129  However, in conjunction with other pre-
erythrocytic antigens, LSA-1 antibodies have been reported to be protective of 
symptomatic illness.136, 139   
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Summary 
The burden of Pf-malaria infections is not independent of other infectious 
diseases circulating in a community. The repeated interaction of Pf-malaria parasites 
with persistent EBV infections can lead to eBL but the precise mechanism of 
interaction is shrouded in uncertainty. Two critical components to improve our 
understanding of the interaction between these two pathogens are 1) the use of an 
individual-level definition of Pf-malaria that accounts for recurrent Pf-malaria rather 
than acute, and 2) a study time period that allows for an examination of EBV 
persistence and immunity in response to recurrent Pf-malaria exposure. This 
dissertation aimed to incorporate these two missing components to gain further 
insight on the interplay of these two co-factors of eBL.  
The disproportionate burden of Pf-malaria infections in sub-Saharan Africa, 
particularly among children, justified on-going research and treatment to ensure a 
continuing reduction in the rate of illness. Vaccine trials are underway in the hopes 
of creating an effective addition to current malaria control strategies. Yet could 
differences in antibody responses between areas of disparate malaria transmission 
intensities affect the effectiveness of vaccines? Furthermore the reported short 
lifespan of antibodies presents challenges in the development of long-lasting 
immunity. This dissertation aimed to improve the understanding of the differential 
patterns of immunity development between areas of heterogeneous malaria 
transmission intensities, including the decay of immune responses over time.  
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TABLE 2.1.  Summary of Pf-malaria and EBV research related to T-cell response. 
Authors Study Design Results 
Moss80, 
1983 
 
Papua New 
Guinea 
Ecological; adults 
from 
holoendemic and 
sporadic areas 
as well as and 
Caucasian 
controls 
1. Higher regression endpoints for 
individuals in holoendemic area compared 
to control groups. No difference between 
two control groups.  
2.  No differences among three groups to 
anti-EBNA or anti-VCA. 
3. Spontaneous transformation of uninfected 
cells in individuals from holoendemic area 
but not control groups. 
 
Kataaha53, 
1984 
 
UK 
Laboratory; 
adults with no 
history of Pf-
malaria infection 
1. EBV can induce normal lymphocytes into 
LCL in vitro. 
2. P. falciparum products can induce normal 
lymphocytes into LCL in vitro. 
 
Whittle78, 
1984 
 
Gambia 
Case-control; 
During/post P. 
falciparum 
infection in 
children 5-18 
years old. 
1. High regression indices during acute P. 
falciparum infection.  
2. During acute P. falciparum infection, 
number and proportion of T-helper cells was 
reduced. 
3. Proportion of B-lymphocytes increased 
during acute P. falciparum infection.   
 
Gunapala69, 
1990 
 
UK 
Case-control; 
acute P. 
falciparum 
infection in UK 
residents aged 
11-51 years, 
healthy EBV 
seropositive UK 
adults   
1. A larger proportion of cases had higher 
regression endpoints than controls.  
2. Cases had higher numbers of B-
lymphocytes and CD8+ T-cells; ratio of 
CD4:CD8 reduced compared to controls. 
3. The proportion of lymphocytes 
transformed to LCL in cases was 
significantly higher than controls. 
4. Cases had higher anti-VCA titers than 
controls. 
 
Moormann35, 
2007 
 
Kenya 
 
Ecological; 
Children 1-14 yo 
from 
holoendemic and 
sporadic areas 
1. No difference in cytotoxic T-cell response 
between two areas but in holoendemic area 
observed a loss of T-cell response in 
children 5-9 years old compared to younger 
and older children. 
2.  Children in holoendemic area had 
significantly less Interleukin 10 responses to 
EBV lytic peptides than those in the 
sporadic area.  
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Authors Study Design Results 
 
Njie79,  2009 
 
Gambia 
Case-control; 
Children 3-14 
years old with 
symptomatic P. 
falciparum, age-
matched children 
with no 
parasitemia, 
Gambian adults 
not parasitemic, 
UK adults with no 
parasitemia, all 
seropositive for 
EBV 
1. Gambian adults had significantly higher 
viral loads than UK adults. 
2. Gambian children with acute Pf-malaria 
had viral loads 5-6 times higher than control 
children (p<0.001). 
3. EBV loads higher in children 3-5 years 
old than older children although not 
statistically significant. 
4. No significant difference in EBV loads in 
children with acute Pf-malaria 4-6 weeks 
after infection. 
5. Gambian children had weak T-cell 
responses during acute Pf-malaria infection 
compared to adult controls; recovery levels 
were similar to adult controls (no 
significance testing due to small sample 
size). 
 
 
 
 
 
 
 
 
   
  
 
CHAPTER THREE: DESCRIPTION OF DATA SOURCES 
 
Study Setting 
The Kisumu/Nandi Cohort Study was established in western Kenya, an area located 
within the eBL “Lymphoma Belt” (Figure 2. 2). Two sites with disparate MTI levels 
were selected (Figure 3.1). The first site was located in Kisumu District in Nyanza 
Province, located in the lowlands on the banks of Lake Victoria. Malaria transmission 
in this area has been described as high and perennial, i.e. holoendemic. The other 
site was in Nandi District in the Rift Valley Province, located in the highlands 150 km 
northeast of Kisumu where malaria transmission has been characterized as low, 
unstable and prone to epidemics, i.e. hypoendemic. These areas were referred to by 
their district names, Kisumu (holoendemic) and Nandi (hypoendemic).   
 
Study Population 
In Kisumu district, Kanyawegi sublocation was selected for participation based on 
interest in the study and willingness of children (with parental permission) to provide 
venous blood samples. An estimated 3,000 individuals reside in the 6-7 villages in 
this sublocation. Fishing was the predominant occupation. The Kipsamoite 
sublocation in Nandi District was also selected and similar to Kanyawegi, there were 
6-7 villages with an estimated population of 3,500 residents. Subsistence farming 
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was the main occupation in this area. In both locations, homes were built using 
locally available materials. 
 
Study Sampling 
Local meetings were held to introduce and explain the purpose of the study to 
community members. Study staff waited to enroll children for a few months after the 
introductory meetings to provide parents an opportunity to consider the study.  
Each household and household member had been assigned a unique study 
identification number in 1999 for a demographic study. This information was used to 
randomly sample households for inclusion in the study. The number of participants 
enrolled from each village was set to ensure proportional geographic representation 
of each study site. Written informed consent was obtained from parents or guardians 
of study participants. 
Investigators enrolled a total of 236 children. Based on the age-incidence of 
eBL in western Kenya, investigators made an effort to enroll approximately the same 
number of children within the following age groups: 2-4 years, 5-9 years, and 10-14 
years (Table 3.1). It should be noted during the enrollment process, 13 children aged 
5 months - 23 months and 2 teenagers aged 15 year olds were enrolled. 
Investigators also enrolled approximately the same ratio of children by sex.  
 
Selection Criteria 
The following inclusion criteria were used for enrollment in the study: 
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- Permanent residency in the study site as defined by sleeping in the home at 
least 10 months of the year; 
- “Healthy” appearance as assessed by the clinical officer (i.e., no signs of 
chronic illness or malnutrition); 
- Parental consent for blood sample collection. 
 
The following criteria were used to exclude children from the study: 
- Clinical officer observed signs of severe Pf-malaria infection; 
- HIV infection was known or suspected. 
 
Data Collection 
Three surveys were conducted between July, 2002 and August, 2004. The timing of 
the surveys and corresponding number of participants are summarized in Table 3.2.  
During each survey, a standardized form was used to collect general 
demographic information (e.g., date of birth, sex), and malaria related information 
(e.g. bednet use). A copy of the form can be found in Appendix A. In addition, blood 
was collected for Pf-malaria testing (thick and thin blood smears), Pf-malaria 
serology testing (AMA-1 and MSP-142 to 3D7 and FVO strains, and LSA-1) and EBV 
testing (EBV-specific CD8+ T cell IFN-γ). 
 
Human Subjects Research 
The Office of Human Research Ethics at the University of North Carolina at Chapel 
Hill determined the proposed research (Study # 08-1117) did not require IRB 
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approval as it did not constitute human subjects research. The original study was 
under the auspices of a National Institute of Health K08 Award (Principal Investigator 
– Dr. Moormann), AI51565, and approved by the University Hospitals of Cleveland, 
Case Western Reserve University IRB and the Ethical Review Committee for the 
Kenya Medical Research Institute. Letters from these organizations can be made 
available upon request to Dr. Moormann (by phone at (508) 856-8826 or by email at 
ann.moormann@umassmed.edu). 
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TABLE 3.2. Summary of survey periods and corresponding number of participants. 
Study Period Number of Participants 
July– August 2002 
(baseline) 236 
February–March 2003 
(6-month follow up) 210 
July–August 2004 
(2-year follow up) 174 
 
 
 
 
 
 
 
   
 
 
CHAPTER FOUR: METHODS 
 
Specific Aim 1 
To assess the effect of recurrent Pf-malaria exposure on Epstein Barr Virus latent 
and lytic antigen CD8+ T-cell IFN-γ responses over time. 
 
Study Design Overview 
Using the Kisumu/Nandi Cohort, we assessed the cumulative effect of repeated Pf-
malaria infections on EBV latent and lytic antigen CD8+ T-cell IFN-γ responses over 
time. We used data from all three surveys from this cohort because the setting (i.e., 
holoendemic and hypoendemic) permitted exploration of district- and individual-level 
definition of recurrent Pf-malaria infections. Furthermore, EBV and Pf-malaria test 
results at three time points over a two-year period were available to address our 
objective. 
 
Selection Criteria 
Inclusion criteria: All cohort members who were seropositive for EBV at baseline. 
Exclusion criteria: Children with uninterpretable EBV latent and lytic antigen CD8+ T-
cell IFN-γ responses.  
 
Measurements
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Outcome: EBV latent and lytic antigen CD8+ T-cell IFN-γ response from each of the 
three survey periods was a dichotomous variable. Originally measured as a 
continuous variable by the IFN-γ enzyme-linked immunospot (ELISPOT) assay, the 
Χ2 Fisher’s Exact Test was used to classify responses (1=positive response, 0=no 
response).  
  
Exposure: Two definitions of Pf-malaria were used to explore the impact of Pf-
malaria at the district and individual level.  
- At the district level, recurrent Pf-malaria exposure was a time-invariant 
exposure defined according to the level of malaria transmission 
(1=Kisumu - holoendemic, 0=Nandi - sporadic).  
- At the individual level, recurrent Pf-malaria infection was a time-varying 
exposure defined as the cumulative average of Pf-malaria infections 
(ranges from 0 to 1 at each survey period, where 1= parasitemia detected 
at present and previous survey periods and 0=no parasitemia detected at 
present or previous survey periods. ).  
 
Additional covariates:  
At the individual level, age, district of residence, HIV status, nutritional status, 
schistosomiasis infection, sex, and socioeconomic status (SES) have been identified 
as potential confounders of the exposure-outcome relationship.  
- HIV testing was not conducted as part of study activities; unmeasured 
potential confounder.  
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- Nutritional status was not assessed; unmeasured potential confounder. 
- Schistosomiasis testing was not conducted; unmeasured potential 
confounder.  
- Information on SES was not collected; unmeasured potential confounder. 
 
Age and sex will be included in our analysis as covariates.  
- Age was modeled as a time-varying covariate using dummy indicators. 
The categories were selected for comparison with previous work (0-4 
years, 5-9 years, >10 years). The >10 year age group was used as the 
referent group. 
- District of residence (site) was a time-invariant dichotomous variable 
(1=Kisumu, 0=Nandi). 
- Sex was a time-invariant dichotomous variable (1=Male, 0=Female). 
- Survey time period was modeled as a time-invariant covariate using 
dummy indicators. The baseline survey period was used as the referent 
group. 
 
Data Analysis 
We used weighted log-binomial regression models with generalized estimate 
equations (GEE) and robust variance estimators to characterize variation of EBV 
latent and lytic antigen CD8+ T-cell IFN-γ responses over time with 1) recurrent Pf-
malaria exposure (district) as an exposure, and 2) recurrent Pf-malaria infection 
(individual) as an exposure.   
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The GEE approach was used account for repeated outcome measures.147, 148  
Random effects models could have been used, however the GEE was preferred for 
our analyses because we were interested in estimating the population-averaged 
change in the outcome for a unit change in the exposure whereas random effects 
models estimate the change in the outcome for each cluster in the population.149 A 
limitation of the GEE approach is that to estimate robust standard errors, large 
numbers of clusters with few repeated measures are needed. 149 Fortunately the 
Kisumu/Nandi cohort fulfilled this criteria as it was composed of 230 clusters (i.e., 
subjects) with three repeated measures.149  
GEEs use a “quasi-likelihood” approach, an extension of the maximum 
likelihood estimation.147, 148  Estimates are interpreted similarly to linear or logistic 
regression models.150, 151  
The GEE takes the same form as the Generalized Linear Model (GLM)  
                               p 
g(μ) = β0 + Σ βh Xh 
                       h=1 
where μ is the mean response E(Y), g(μ) is a function of the mean, β0 is the 
baseline mean when all predictor variables equal 0, p are independent variables, Xh 
represents the vector of predictor variables, and βh is the mean change when Xh 
=1.150  
 The difference between GLM and GEE is the underlying assumptions and 
approach to estimating the parameters and variances.150, 151 Both models require 
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specification of the link function and variance function;  however, GEEs require 
specification of the working correlation matrix.150, 151 The inclusion of the correlation 
parameters allows GEE to model within-subject correlation.150, 151 
In our analyses we used the independent as the “best guess” for the working 
correlation matrix; the independent working correlation matrix assumes there is no 
correlation within a subject when calculating the point estimate.150, 151 We also used 
robust standard errors which provided unbiased estimates even if the working 
correlation matrix was inaccurate. We used the generalized Wald Test to build the 
final multivariable model as a quasi-likelihood analysis does not generate the 
Likelihood Ratio test commonly used for model comparisons.150 
An important assumptions when using GEE is that data are missing 
completely at random; missingness of data is independent of observed and 
unobserved data.150 We had missing observations in the two subsequent follow-up 
surveys. Upon examination of the pattern of missing observations, we concluded 
missingness was related to age therefore our data were not missing completely at 
random. We weighted the final model using inverse probability weights. A summary 
of this approach is provided in Appendix B.    
 
Descriptive Analysis: Frequencies and proportions were calculated for all 
measurements and summarized in tables or figures.  Continuous outcomes were not 
normally distributed therefore data were described using medians and non-
parametric testing was used to identify any differences between levels of a variable. 
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Bivariable Analysis:   The crude relationship between the exposure-outcome was 
explored using the log-binomial regression with GEE.  Covariate-outcome 
relationships were also explored. Findings from the analyses were summarized in 
tables and figures.  
 
Assessment of Effect Measure Modification: Covariates were initially examined as 
potential effect measure modifiers (EMM) of the exposure-outcome relationship. One 
at a time, the covariate (main effect) and an exposure-covariate interaction term 
were added to the crude model (interaction model). The generalized Wald test was 
used to compare the crude and interaction models to test the significance of the 
interaction term.  Any covariates significant at an alpha-level of 0.20 or less were 
classified as EMM and included in the final model. All models were stratified by 
district of residence. 
 
Assessment of Confounding: Covariates not identified as EMM were assessed as 
potential confounders. Causal diagrams for the relationship between Pf-malaria 
exposure (district) and repeated infection (individual) are presented in Figure 4.1. 
District level –No additional covariates were included in the model. Individual level – 
Age has continuously been reported as a confounder of the exposure-outcome 
relationship therefore it was adjusted for in multivariate models. Sex and survey 
period were assessed as potential confounders; they did not lead to a >10% change 
in the unadjusted PR but were included in the final model.149  
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Multivariable Analysis: We began our analysis with a fully adjusted weighted log-
binomial model including the exposure, EMMs, and confounders. We used the 
independent working correlation matrix with robust variance estimators. All 
measured covariates were included in the model as EMM or confounder therefore 
we did not our fully adjusted model was or finalized model. 
 
Power 
Our study population was fixed; we simulated data to calculate power estimates 
using the GEE approach with three repeated measures examining the effect of Pf-
malaria exposure (district) at a 0.05 two-sided significance level. The power 
estimates for recurrent Pf-malaria exposure (district) for both lytic and latent pools of 
EBV-specific CD8+ T-cell IFN-γ response are summarized in Figure 4.2.  We had 
80% power to detect a PR of 1.93 in EBV-specific CD8+ T-cell IFN-γ response (lytic) 
as a result of Pf-malaria exposure.  We had over 80% power to detect a PR of 1.96 
in specific CD8+ T-cell IFN-γ response (latent) as a result of Pf-malaria exposure. 
 
Limitations 
There were several potential limitations of Specific Aim 1.   
- Interpreting findings from models using a district-level definition of recurrent 
Pf-malaria exposure are subject to the ecological fallacy whereby population-
based estimates are attributed to the individual. We took caution when 
making interpretations of our results, highlighting this potential limitation. 
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- The individual-level definition of recurrent Pf-malaria infection may not 
accurately reflect the true experience of participants. Between baseline and 
subsequent follow-up surveys, participants may have had Pf-malaria 
infections which were not captured by this study design, especially in the 18 
month gap between the last two follow-up surveys.   
- Testing to confirm HIV status was not conducted; children were deemed 
healthy by clinician judgment. Although HIV is a potential confounder in the 
association of Pf-malaria infection and EBV, it does not appear HIV infection 
was present in this cohort at the time of the study. At the time of the study, 
HIV treatment was not readily available in Kenya and as a result, HIV infected 
individuals often died within two years of HIV-related symptom onset. 
Subsequent follow up of these children, as recent as 2009, found no deaths 
among the children.  
- Although Schistosomiasis infection was not conducted, an examination of the 
causal diagram between the exposure-outcome identified age and sex as 
measured antecedents of schistosomiasis infection (schistosomiasis was 
identified as a collider); adjusting for a collider may bias our estimate. Hence 
the lack of schistosomiasis testing for children is unlikely to bias our results.   
- Nutritional status was not measured; children enrolled in the study were 
deemed healthy by clinician judgment with no obvious signs of 
malnourishment. Hence, nutritional status was unlikely to be a potential 
confounder at the time of the study.  
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- SES was an unmeasured potential confounder. Families living in villages at 
both districts were likely to be classified as low SES as the main occupation 
was fishing (Kisumu) and farming (Nandi), with homes constructed of locally 
available materials. Given the SES composition of the villages, it appears 
SES was not a potential confounder at the time of the study. 
 
Specific Aim 2 
a. To describe malaria antibody responses among children in malaria holoendemic 
and hypoendemic areas, contrasting any differences between the areas.  
 
b. To describe the relative change in malaria antibodies over time in malaria 
holoendemic and hypoendemic areas, highlighting any differences between the 
areas. 
 
 
Study Design Overview  
We used data collected in July-August 2002 (baseline) and February-March 2003 
(six-month follow) from the Kisumu/Nandi Cohort to describe Pf-malaria antibody 
responses. This cohort was amenable for our objective because data were available 
from two districts characterized by different malaria transmission intensities. In 
addition, Pf-malaria-specific antibody test result were available. 
 
Selection Criteria  
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Inclusion criteria: All cohort members.  
Exclusion criteria: Children with uninterruptable antibody results.  
 
Measurements and Analysis Plan – Specific Aim 2a 
Outcome: Dichotomous IgG responses to AMA-1 3D7, AMA-1 FVO, MSP-142 3D7, 
MSP-142 FVO, and LSA-1 where 1=positive, 0=negative. Originally measured in 
mean fluorescence intensity (MFI), we standardized results into arbitrary units (AU) 
to account for plate-to-plate variability. Standardization was done by dividing the 
each participant’s MFI antibody response by the negative controls’ mean + three 
standard deviations. AU>1 were classified as a positive IgG response.  
 
Exposure: Our analysis was descriptive therefore age, parasitemia status, and sex 
were treated as exposures.   
- Age was a categorical variable: 0-4 years, 5-9 years, >10 years. Age was 
defined as the child’s age at the time of the survey.  
- Parasitemia status was a dichotomous variable (1=parasitemic, 0=not 
parasitemic).  
- Sex was a dichotomous variable (1=Male, 0=Female). 
 
Descriptive Analysis: Frequencies and proportions were calculated and summarized 
in tables and figures. Median AU values were calculated for each IgG response and 
summarized in a table. Medians were used because the distribution of the 
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continuous outcome was not normally distributed. Data were stratified by district of 
residence. 
 
Bivariable Analysis:   All analyses were stratified by district of residence. The Chi-
square test and Cochran Armitage trend test were used to assess any significant 
differences among the levels of each exposure as well as to compare responses 
between the two districts. Spearman’s rank correlation coefficients were used to 
examine any correlation between outcomes.  
 
Measurements and Data Analysis Plan – Specific Aim 2b 
Outcome: Continuous AU values of AMA-1 3D7, AMA-1 FVO, MSP-142 3D7, MSP-
142 FVO, and LSA-1 antibodies measured as relative change over six-months.  
 
Relative change was calculated using the following formula: 
= (IgG response at six-month follow-up – IgG response at baseline) 
                                  IgG response at baseline. 
 
Exposure: Our analysis was descriptive therefore age group, parasitemia status, and 
sex were treated as exposures.   
- Age was a categorical variable: 0-4 years, 5-9 years, >10 years. Age was 
defined as the child’s age at the baseline survey.  
- Parasitemia status was a categorical variable: 
o Parasitemia at both times 
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o Parasitemia at baseline survey only 
o Parasitemia at six-month follow-up survey only 
o Aparasitemic at both surveys. 
- Sex was a dichotomous variable (1=Male, 0=Female). 
 
Descriptive Analysis: The distribution of the continuous outcome was examined and 
was not normally distributed. Therefore we used medians to describe the data. Data 
were stratified by district of residence and summarized using boxplots and tables. 
 
Bivariable Analysis:   All analyses were stratified by district of residence. Non-
parametric tests were used to identify significant differences between levels of each 
exposure as well as to compare responses between the two districts. Exact tests 
were used for small samples sizes. An extension of the Wilcoxon rank-sum test was 
used to assess for trends of ordinal exposures. Spearman’s rank correlation 
coefficients were used to assess any correlation in the relative change of antibody 
responses between outcomes.  
 
Missing observations: Surveys were conducted on 210 of the original 236 children at 
six-month follow up. This represented an 11% loss to follow-up. We did not identify 
any significant differences by age group or sex between children who did and did not 
participate in the six-month follow-up survey. 
 
Limitations – Specific Aim 2 
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There were several potential limitations of Specific Aim 2.   
- Cross-sectional studies measure exposure and outcome at one point in time. 
It was possible that children with elevated antibody responses cleared their 
parasitemia just before the survey. Therefore we may not have captured 
accurately the relationship between parasitemia status and antibody 
response. However, this would have predominantly been an issue in Kisumu 
where children experienced Pf-malaria infection more often than Nandi 
children. Given the large proportion of children who had parasitemia detected 
in Kisumu (>76%) at both surveys, this issue was likely to be minimal.  
- The use of AU permitted standardization of antibody responses to account for 
plate-to-plate variability. However there is no intrinsic meaning of AU values. 
In addition, cutoffs for AU values differ across studies therefore and they 
cannot be directly compared across studies although directionality of 
responses are comparable. 
- Caution must be taken when interpreting the relative change in antibody 
responses. A 200% increase in antibody response in a child originally 
classified as a negative responder does not imply the child has become a 
positive responder. 
- We cannot say if observed differences in antibody responses reflect 
functional differences. 
- Due to limited power, we were unable to detect small yet meaningful 
differences. For example, we had few children in Kisumu (n=6) who were 
aparasitemic at both surveys and few children in Nandi (n=5) who were 
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parasitemic at both surveys. Hence we were unable to detect differences in 
the median relative change in IgG response by parasitemia status for most 
antibodies. 
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CHAPTER FIVE: Recurrent Plasmodium falciparum Malaria Infections in 
Kenyan Children Diminish T-cell Immunity to Epstein Barr Virus Lytic but not 
Latent Antigens 
  
ABSTRACT  
Background.  Plasmodium falciparum malaria (Pf-malaria) and Epstein Barr Virus 
(EBV) infections coexist in children at risk for endemic Burkitt’s lymphoma (eBL); yet 
studies have only glimpsed the cumulative effect of Pf-malaria on EBV-specific 
immunity. 
Methods.  Using pooled EBV lytic and latent CD8+ T-cell epitope-peptides, IFN-γ 
ELISPOT responses were surveyed three times among children (10 months to 15 
years) in Kenya from 2002-2004.  Prevalence ratios (PR) and 95% confidence 
intervals (CI) were estimated in association with Pf-malaria exposure, defined at the 
district-level (Kisumu: holoendemic; Nandi: hypoendemic) and the individual-level. 
Results.  We observed a 46% decrease in positive EBV lytic antigen IFN-γ 
responses among 5-9 year olds residing in Kisumu compared to Nandi (PR: 0.54; 
95% CI: 0.30-0.99).  Individual-level analysis in Kisumu revealed further impairment 
of EBV lytic antigen responses among 5-9 year olds consistently infected with Pf-
malaria compared to those never infected.  There were no observed district- or 
individual-level differences between Pf-malaria exposure and EBV latent antigen 
IFN-γ response. 
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Conclusions.  The gradual decrease of EBV lytic antigen but not latent antigen IFN-
γ responses after primary infection, suggests a specific loss in immunological control 
over the lytic cycle in children residing in malaria holoendemic areas; further refining 
our understanding of eBL etiology. 
 
INTRODUCTION 
Plasmodium falciparum (Pf) malaria and Epstein Barr Virus (EBV) have been 
identified as co-factors in the pathogenesis of endemic Burkitt’s lymphoma (eBL) 2 
which is estimated to account for 70% of cancers among children in equatorial Africa 
3, 4.  In areas with intense perennial malaria transmission (holoendemic), the highest 
incidence of eBL is in children aged 4-8 years 17, 22, 25, 27, 29, 74, in contrast to areas 
with low malaria transmission (hypoendemic) where eBL is rarely reported 7, 25, 30. 
 It has been hypothesized that Pf-malaria infections promote eBL in two 
mutually-compatible ways.  In developing countries, most children experience 
primary EBV infection by 3 years of age, followed by life-long infection in memory B-
lymphocytes 5, 19.  P. falciparum induces polyclonal B-cell expansion and lytic EBV 
reactivation 61, thus increasing the number of latently-infected B-cells.  In otherwise 
healthy individuals, interferon-gamma (IFN-γ) secreting cytotoxic CD8+ T-cells 
mediate immunosurveillance of EBV 19, 22, 35, 50, 52, 152.  Repeated Pf-malaria 
infections could hence lead to exhaustion or hypo-responsiveness of EBV latent or 
lytic antigen CD8+ T-cells, thus increasing the chance for this EBV-associated 
malignancy to arise. 
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 Limited evidence supports an impaired EBV-specific T-cell response in 
association with Pf-malaria.  Using an in vitro regression assay as a measure of 
cytotoxicity, children with acute Pf-malaria demonstrated a transient loss of control 
over B-cell outgrowth 76-78.  Furthermore, case-control studies comparing acutely Pf-
malaria infected individuals with healthy adults came to the same conclusion 69, 79.  
However, the cumulative effect of repeated often asymptomatic Pf-malaria infections 
on EBV persistence has not been thoroughly studied. 2, 29, 31, 32  Two ecological 
studies provide the minimum understanding we have on the relationship.  A study 
among adults found a loss of EBV-specific T-cell control among those exposed to 
holoendemic compared to hypoendemic malaria 80.  A second study only found 
significantly lower EBV latent and lytic antigen IFN-γ responses in children 5-9 years 
old residing in the holoendemic area compared to other age groups and children 
from a hypoendemic area 35. 
 The objective of this study was to examine the influence of cumulative Pf-
malaria on EBV latent and lytic antigen CD8+ T-cell IFN-γ ELISPOT responses in 
children over a two-year period. 
 
METHODS 
The Kisumu/Nandi cohort has been previously described 59.  In brief, the cohort 
consists of 236 children, randomly selected and between 10 months and 15 years at 
enrollment, from two districts in western Kenya with disparate Pf-malaria 
transmission intensities: Kisumu is characterized as holoendemic and Nandi as 
hypoendemic.  Due to the age-related incidence of eBL, an equal distribution of 
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children by age and sex were enrolled from each area: children 0-4 years have an 
elevated risk of eBL whereas 5-9 year olds are at highest risk and >10 years old 
have the lowest risk.  Data were collected from 2002-2004 using a standardized 
survey.  Three face-to-face interviews were conducted at baseline (July-August 
2002), six month follow-up (February-March 2003), and two-year follow-up (July-
August 2004). Blood was also collected for malaria and EBV testing. 
 Pf-malaria infection was confirmed on thick and thin blood smears by 
microscopy.  Testing of EBV-specific T-cell response by IFN-γ ELISPOT has been 
previously described 35.  Lytic (BRLF1, BZLF1, and BMLF1) and latent (Epstein-Barr 
nuclear antigen [EBNA] 3A, EBNA 3B, and EBNA3C) antigens were selected and 
pooled for testing.  One positive control (mitogen phytohemmagglutinin [PHA]) was 
used to stimulate wells and a negative control (phosphate buffer saline [PBS]) was 
used to measure background IFN-γ response in unstimulated wells.  Assays were 
condensed into a three-week period using the same reagents and personnel to 
minimize inter-assay variability.  Cytotoxic T-lymphocyte (CTL) ImmunoSpot 
scanning and imaging software (version 4; Cellular Technology Ltd, Shaker Heights, 
OH) was used to count the number of spot-forming units (SFU) per well; results were 
expressed as SFU per million peripheral blood mononuclear cells (PBMC).  Using a 
two-sided Fisher’s exact test (P < .05), EBV lytic and latent epitope-peptide CD8+ T-
cell IFN-γ responses were categorized as positive or negative.  A positive response 
was recorded if the proportion of SFUs in the stimulated well was significantly 
different from the proportion of SFU in the unstimulated well.  The magnitude of 
response was calculated by subtracting the SFU in PBS wells (negative control) 
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from the SFU in the stimulated wells.  The median value for the negative control 
wells was 4 SFU per million PBMCs (range 0 to 772 SFU/million PBMC).  Median 
values were calculated among positive responders only. 
 Analyses were restricted to EBV seropositive children at baseline 59.  We 
used two definitions of cumulative Pf-malaria.  First, Pf-malaria exposure was 
defined according to the malaria transmission intensity of the district (district-level 
definition):  Kisumu (holoendemic) or Nandi (hypoendemic).  Next, Pf-malaria 
infection was defined as the cumulative average of P. falciparum infection 
(parasitemia) in a participant over the three survey periods (individual-level 
definition).  The value ranged from 0 (never infected) to 1 (always infected); results 
and discussion focus on children who were always infected (referred to as recurrent) 
and never infected.  With the individual-level definition, we also included the 
covariates age group, district, sex, and when the survey was conducted (referred to 
as survey period) in the analysis.  We first examined covariates as potential effect 
measure modifiers using an a priori cutoff of P = .20.  In the absence of evidence of 
effect measure modification, we included covariates in the model as potential 
confounders. 
 For descriptive analyses, we used the χ2 statistic to measure associations 
between categorical exposures and outcomes.  We used the two-sided Wilcoxon 
rank sum (Mann-Whitney U)/Kruskal Wallis test for continuous outcomes.  For 
multivariable analyses, we used weighted log-binomial regression with robust 
variances to estimate the prevalence ratios (PR) and corresponding 95% confidence 
intervals (CI).  We used generalized estimating equations (GEE) with robust 
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variance estimators to account for correlation due to repeated measurements.  A 
weighted model with inverse probability weights was used to address missing 
observations due to children not participating in all surveys.  An explanation of our 
approach can be found in Appendix B.  We also conducted complete case analyses 
and found no differences in the PR or 95% CI; therefore we report results from the 
weighted analyses.  Data were analyzed in SAS 9.1.3 (Cary, NC). 
 Written informed consent was obtained from a parent or guardian of the 
participant.  This study was approved by the Institutional Review Boards at the 
University Hospitals of Cleveland, Case Western Reserve University where Dr. 
Moormann was affiliated at the time this study was done and also obtained from the 
Ethical Review Committee for the Kenya Medical Research Institute.  It was deemed 
exempt by the Institutional Review Board at the University of North Carolina at 
Chapel Hill. 
 
RESULTS 
Participant Summary 
Of the 236 children enrolled, 230 (97.5%) were seropositive for EBV 59.  Our 
weighted analysis included 149 children who participated in all surveys and had 
interpretable EBV-specific T-cell responses (Table 5.1).  The age and sex 
distribution between the districts were not significantly different (P = .11 and P = .30, 
respectively).  Children in Kisumu experienced more Pf-malaria infections than 
children in Nandi (P < .001); only 3% of Kisumu children were never infected 
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compared to 78% in Nandi.  This was despite a classically defined malaria outbreak 
in Nandi during the survey periods (Figure 5.1). 
 
The Magnitude of EBV-specific IFN-γ Responses Did Not Differ Significantly by 
Malaria Endemicity 
The proportion of positive IFN-γ responses to PHA (positive control) demonstrates 
that children from both districts were equally able to elicit an IFN-γ response 
indicating no global signs of immune dysfunction (Table 5.2).  There were no 
significant differences in median values of EBV lytic or latent CD8+ T-cell IFN-γ 
responses between children of similar age groups across districts.  Therefore, Pf-
malaria exposure does not appear to influence the magnitude of EBV-specific IFN-γ 
responses. 
 
Pf-malaria Exposure (District-level) and EBV-specific T-cell IFN-γ Responses 
EBV lytic antigen CD8+ T-cell IFN-γ responses.  We observed a few intriguing 
patterns in the prevalence of positive EBV lytic antigen CD8+ T-cell IFN-γ response 
when children were stratified into age groups by their baseline age (age group 
cohorts) (Figures 5.2A and 5.2C).  In Kisumu, the prevalence of positive responses 
in the 0-4 year and 5-9 year cohorts decreased from baseline to first follow-up, but 
remained unchanged in the  >10 year cohort.  By the second follow-up, responses 
increased among the 0-4 and 5-9 year cohorts while responses decreased in >10 
year cohort.  However, children in the 5-9 year cohort had the lowest prevalence at 
each survey period.  In Nandi, responses declined in all age group cohorts from 
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baseline to first follow-up and remained almost unchanged in the 5-9 year and >10 
year cohorts by the second follow-up.  In the 0-4 year cohort, however, responses 
increased.  The patterns and prevalence of responses among the age group cohorts 
were similar at all survey periods, varying <10%. 
 Using the district-level definition of Pf-malaria and the weighted model 
described earlier, we estimated the prevalence of positive responses in Kisumu was 
0.70 (95% CI: 0.45-1.08) times the prevalence in Nandi although this 30% difference 
was not significant.  In Kisumu, there were no significant differences in positive 
responses in children 0-4 years (PR: 1.39, 95% CI: 0.60-3.20) and 5-9 years (PR: 
0.74, 95% CI: 0.37-1.48) when compared to children >10 years (Figure 5.3A).  
Likewise in Nandi, the prevalence of positive responses in children 0-4 years (PR: 
1.10, 95% CI: 0.60-2.02) and 5-9 years (PR: 1.04, 95% CI: 0.61-1.76) did not differ 
significantly from children >10 years.  When similar age groups were compared 
between districts, we detected a significant difference in children 5-9 years where 
the prevalence of positive responses in Kisumu was 0.54 (95% CI: 0.30-0.99) that of 
children in Nandi (Figure 3A).  No other differences by age group were found. 
EBV latent antigen CD8+ T-cell IFN-γ responses.  Examining the patterns in the 
prevalence of positive EBV latent antigen CD8+ T-cell IFN-γ response by age group 
cohorts, there was variation within and between districts (Figures 5.2B and 5.2D).  In 
Kisumu, the prevalence at baseline was highest among the 0-4 year cohort but then 
decreased to nearly the same prevalence as the other age group cohorts.  In Nandi, 
there was a decreasing trend from baseline to second follow-up for the 0-4 year and 
5-9 year cohorts.  However, the >10 years cohort had the highest prevalence of 
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response at baseline that decreased by the first follow-up but rebounded by the 
second follow-up. 
 From our weighted model, we observed the prevalence of positive responses 
in Kisumu was 0.80 (95% CI: 0.51-1.25) times the prevalence in Nandi, although not 
significant.  In Kisumu, the prevalence of positive responses in children 0-4 years 
(PR: 1.93, 95% CI: 0.91-4.13) and 5-9 years (PR: 1.22, 95% CI: 0.61-2.45) was not 
significantly different from children >10 years, although there was a decrease in 
prevalence with increasing age group (Figure 5.3B).  Similarly in Nandi, responses 
among children 0-4 years (PR: 0.72, 95% CI: 0.35-1.48) and 5-9 years (PR: 0.84, 
95% CI: 0.47-1.49) did not differ significantly from children >10 years old, although 
there was a slight increase in response with increasing age.  Despite these 
interesting trends, there were no significant differences in the prevalence of positive 
responses when similar age groups were compared between districts. 
 
Pf-malaria Infection (Individual-level) and EBV-specific T-cell IFN-γ Responses 
EBV lytic antigen CD8+ T-cell IFN-γ responses.  Using the individual-level definition 
of Pf-malaria and weighted model described earlier, we found the association 
between recurrent Pf-malaria infections and EBV lytic antigen CD8+ T-cell IFN-γ 
response varied by age group and survey period.  We therefore used two models.  
In the first model, we stratified results by age group, while adjusting for sex and 
survey period.  Similarly in the second model, we stratified by survey period while 
adjusting for sex and age group. 
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 We noted three observations from our analysis.  First, the PR of recurrent Pf-
malaria infections and positive IFN-γ responses among Kisumu children were 
consistently lower than Nandi children for all age groups and survey periods (Table 
5.3).  In general, there is a two-fold difference in the PR between Kisumu and Nandi 
although not significant (P = .32).  Secondly, the association between recurrent Pf-
malaria infections and IFN-γ responses varied by age group.  In both Kisumu and 
Nandi, the prevalence of positive responses among children 0-4 years with recurrent 
Pf-malaria infections was higher than that of similarly aged children never infected.  
In Nandi, the difference was statistically significant.  Finally, the PR of recurrent Pf-
malaria infections and IFN-γ responses to EBV lytic antigens varied by survey period 
in both districts.  At baseline, for both districts, the PR of positive responses among 
children with recurrent Pf-malaria infections was greater compared to children never 
infected; this result was statistically significant in Nandi, but not Kisumu.  However, 
the PR decreased at subsequent study periods; the prevalence of positive 
responses among children with recurrent Pf-malaria infection diminished over time 
compared to children never infected.  This could reflect functional diminishment of 
responsive EBV lytic antigen T-cells under continuous pressure from Pf-malaria. 
EBV latent antigen CD8+ T-cell IFN-γ responses.  Using our weighted model, we did 
not observe any variation by age group (Table 5.4) or survey period (data not 
shown).  In Kisumu, for all age groups, the adjusted prevalence of positive EBV 
latent antigen CD8+ T-cell IFN-γ response was higher among children with recurrent 
Pf-malaria infections compared to those never infected (Table 5.4).  There was a 
two-fold difference in the PR for children 0-4 years and >10 years with recurrent Pf-
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malaria infections than children 5-9 years.  In Nandi, children 0-4 years with 
recurrent Pf-malaria infections had fewer positive responses than children never 
infected, and a PR that was three-fold lower than older children.  However, children 
in older age groups with recurrent Pf-malaria infections had higher positive 
responses than similarly aged children never infected.  Despite estimates for Kisumu 
and Nandi being imprecise and not statistically significant, the observations suggest 
that children 5-9 years in Kisumu are unable to mount the type of T-cell response as 
younger and older children.  Meanwhile, in Nandi, the increasing PR with age may 
reflect how a maturing immune system, not continuously exposed to Pf-malaria, is 
able to induce a T-cell response to latent antigens even when co-infected with Pf-
malaria. 
 
DISCUSSION 
Our study demonstrates that the prevalence of positive EBV lytic- but not latent-
antigen CD8+ T-cell IFN-γ responses decreases in a malaria holoendemic area and 
not a hypoendemic area.  This suggests that children repeatedly infected with Pf-
malaria eventually lose functional IFN-γ producing CD8+ T-cells in response to EBV 
lytic antigens. In an effort to control viral replication induced by recurrent Pf-malaria 
infections 61, we hypothesize that EBV lytic antigen CD8+ T-cells have become 
exhausted and unable to produce IFN-γ or alternatively these cells were culled 
through apoptosis.  As a result of the loss of responsive EBV lytic antigen CD8+ T-
cells, more B-lymphocytes could become latently infected by EBV, and thus 
gradually increasing the risk of eBL.  These findings are consistent with previous 
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studies of this cohort, which detected significantly higher median EBV viral load and 
EBV-specific IgG antibodies to EBV lytic and latent antigens in the holoendemic 
compared to hypoendemic area 59, 153. 
 Furthermore, the association between Pf-malaria infections and positive EBV 
lytic antigen CD8+ T-cell IFN-γ responses varied by age group.  The EBV lytic 
antigen deficiency was most pronounced among children 5-9 years old in the 
malaria holoendemic area and was further potentiated in those recurrently infected 
with Pf-malaria.  In our individual-level analysis, these children had the lowest PR of 
positive responses while this same age group in the hypoendemic area appeared to 
be affected little.  Additionally, the patterns observed in the age group cohorts clearly 
showed that the 5-9 year cohort in Kisumu had the lowest prevalence of positive 
responses among all age group cohorts, in both districts, at each survey period.  The 
sustained inability to produce an effective EBV lytic antigen CD8+ T-cell IFN-γ 
response among 5-9 year olds may be an etiologically relevant event in eBL 
development because eBL is most often diagnosed in this age group.  Finally, the 
inconsistency of patterns between age group cohorts within a district suggests there 
is an age-dependent interaction between Pf-malaria and EBV-specific T-cell 
response.  Studies of immune mechanisms that induce exhaustion or deletion are 
needed to understand maintenance of EBV-specific T-cell immunity in children. 
 This study is an important early step to understanding the cumulative effect of 
Pf-malaria infections on EBV-specific T-cell immunity over time.  Availability of data 
over two-years permitted identification of potentially important biological and 
environmental mechanisms that only become apparent over time.  For example, the 
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association between Pf-malaria infection and positive EBV lytic antigen CD8+ T-cell 
IFN-γ responses varied by age group and survey period.  The variation noted with 
age group is expected because there is an age-dependent increase in T-cell 
immunity as children develop protection against Pf-malaria after repeated infections 
154.  Children in malaria holoendemic areas acquire immunity to Pf-malaria and EBV 
during the first years of life, and ongoing studies will compare the development of Pf-
malaria to EBV-specific T-cell memory. 
 Using data, collected during a two-year period, also allowed us to use an 
individual-level definition for Pf-malaria infections.  Unlike other studies, our 
definition accounted for the cumulative effect of Pf-malaria infection which has been 
hypothesized to be critical in the pathogenesis of eBL, rather than the transient 
effect typically observed with acute Pf-malaria infection 2.  However, our definition 
was vulnerable to misclassification because Pf-malaria infection was assessed only 
twice during the two-year follow-up.  Therefore, we may not have captured 
participants’ malaria histories accurately.  This misclassification was likely to be 
differential because children in the holoendemic area were exposed to Pf-malaria 
parasites at a higher frequency, averaging two malaria infections per year, than 
children in the hypoendemic area 122.  Therefore, we may have underestimated or 
overestimated the PR for Pf-malaria and EBV-specific T-cell responses in the 
holoendemic area. 
 A strength of our study was the use of two definitions for Pf-malaria:  1) 
district-level according to malaria transmission intensity, and 2) individual-level 
based on measured Pf-malaria infection.  Although our findings of EBV lytic antigen 
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CD8+ T-cell IFN-γ responses were consistent with both definitions, our findings of 
EBV latent antigen CD8+ T-cell IFN-γ responses were inconsistent.  This may have 
been due to the limited power or an underestimation of the influence of Pf-malaria 
infections in hypoendemic areas.  However, it also highlights the potential pitfall in 
attributing district-level results to the individual, also known as the ecological fallacy.  
The inconsistency may have been due to other factors that differed between the 
districts and unrelated to malaria transmission intensities.  Therefore, we conclude 
that the use of malaria transmission intensity as a surrogate for malaria infection has 
been informative yet future studies should endeavor to prospectively collect Pf-
malaria and EBV co-infections information from individuals to more accurately 
describe this complex relationship. 
 There were several potential confounders that were not captured in our study, 
specifically HIV status, nutritional status, schistosomiasis infection, and 
socioeconomic status.  However, we do not believe the absence of these 
confounders materially affected our findings.  When data were collected in western 
Kenya from 2002-2004, HIV testing in infants was conducted only when medically 
warranted.  All children were examined by a clinician and had no obvious signs of 
illness or malnourishment, and no deaths have been reported as of 2009.  
Schistosomiasis infection was unmeasured yet an examination of the Pf-malaria and 
EBV response relationship indicated adjusting for schistosomiasis infection would 
have biased our analysis.  If measured, participants and their families would likely 
have been classified as low socioeconomic status because the main occupation was 
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fishing (Kisumu) and farming (Nandi) in both rural study areas with homes 
constructed of locally available materials. 
 Our findings on EBV lytic antigen CD8+ T-cell IFN-γ responses were 
consistent with the studies that have used residence area (malaria transmission 
intensity) to explore the cumulative effect of Pf-malaria infections on EBV-specific T-
cell response.  We observed fewer positive EBV lytic antigen CD8+ T-cell IFN-γ 
responses among 5-9 year old than older children 35.  We also identified a reduction 
in EBV-specific T-cell response among children living in a holoendemic compared a 
hypoendemic area 80.  The consistency of our findings with previous studies is 
important given our limited sample size and precision.  Meanwhile, our analysis of 
EBV lytic antigen CD8+ T-cell IFN-γ response at the individual-level supports 
findings from previous studies that used residence area as a surrogate for malaria 
infection. 
 However, we did not detect the same statistically significant district-level 
difference in positive EBV latent antigen CD8+ T-cell IFN-γ responses among 5-9 
year olds as a previous study 35.  This discrepancy may be due to the limited power 
of our study.  Furthermore, the difference between our individual-level analysis and 
the previous study may also be due to the use of a surrogate definition of Pf-malaria. 
 This study design marks a step toward examining the individual-level 
association of Pf-malaria infections and EBV-specific T-cell IFN-γ responses and 
identifies a potential difference between children recurrently infected with Pf-malaria 
compared to children never infected.  To adequately quantify this effect, a 
longitudinal study should be considered which could accurately measure Pf-malaria 
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infection and changes in Pf-malaria and EBV-specific T-cell immunity over time.  The 
temporal aspects of future studies will be vital to elucidating the precise mechanism 
by which repeated Pf-malaria infections affect EBV persistence and immunity. 
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FIGURE 5.2.  Change in the prevalence of positive EBV lytic (A and C) and latent (B and D) antigen CD8+ T-cell IFN-γ 
response by age group at baseline, Kenya 2002-2004. Age group at each survey period is based on age at baseline. In 
Kisumu: 16 (0-4 years), 33 (5-9 years) and 17 (>10 years). In Nandi: 30 (0-4 years), 35 (5-9 years) and 18 (>10 years).  
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TABLE 5.1.  Summary of participants in the Kisumu/Nandi Cohort, Kenya 2002-
2004a 
 
NOTE.  n, number; %, percentage.  
a Data in the table are weighted according to the 149 children who participated in all 
surveys and had interpretable Epstein-Barr virus (EBV) specific CD8+ T-cell IFN-γ 
response. 
 Site Total 
 Kisumu (holoendemic) Nandi (hypoendemic)  
 n % n % n 
Sex      
Male 39 59.1 38 45.8 77 
Female 27 40.9 45 54.2 72 
Age (in years)      
0-4 16 24.2 30 36.1 46 
5-9 33 50.0 35 42.2 68 
>10 17 25.8 18 21.7 35 
Malaria infections      
All surveys 38 57.6 0 0 38 
Two surveys 20 30.3 4 4.8 24 
One survey 6 9.1 14 16.9 20 
Never 2 3.0 65 78.3 67 
      
Total 66  83  149 
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TABLE 5.2.  Prevalence and magnitude of EBV-specific CD8+ T-cell IFN-γ response 
by site of residence and age group,  Kenya 2002-2004a 
 
 EBV lytic antigens EBV latent antigens PHAb 
 n % Median
c 
(range) n % 
Medianc 
(range) n % 
 
Baseline (July-August 2002) 
Kisumu         
0-4 years 7/16 43.8 96 (14-166) 8/16 50.0 43 (20-98) 13/16 81.3 
5-9 years 8/33 24.2 67 (18-170) 6/33 18.2 47 (16-448) 31/33 93.9 
>10 years 5/17 29.4 150 (20-350) 5/17 29.4 46 (16-404) 15/17 88.2 
Nandi         
0-4 years 12/30 34.3 98 (28-836) 8/30 26.7 70 (18-146) 28/30 93.3 
5-9 years 15/35 42.9 50 (22-792) 11/35 31.4 84 (42-668) 33/35 94.3 
>10 years 8/18 22.9 53 (36-304) 8/18 44.4 88 (26-1322) 18/18 100 
 
First follow-up (February-March 2003) 
Kisumu         
0-4 years 4/16 25.0 46 (40-128) 2/16 12.5 55 (32-78) 16/16 100 
5-9 years 1/33 3.0 20 (20) 6/33 18.2 15 (14-132) 31/33 93.9 
>10 years 5/17 29.4 30 (18-162) 2/17 11.8 23 (18-28) 16/17 94.1 
Nandi         
0-4 years 6/30 20.0 98 (24-744) 4/30 13.3 77 (32-128) 26/30 86.7 
5-9 years 8/35 22.9 82 (16-1742) 8/35 22.9 58 (20-248) 34/35 97.1 
>10 years 5/18 27.8 54 (32-382) 3/18 16.7 54 (14-354) 18/18 100 
 
Second follow-up (July-August 2004) 
Kisumu         
0-4 years 5/16 31.3 76 (30-84) 2/16 12.5 106 (64-148) 15/16 93.8 
5-9 years 3/33 9.1 60 (56-150) 3/33 9.1 42 (24-74) 33/33 100 
>10 years 3/17 17.7 250 (40-288) 1/17 5.9 16 (16) 17/17 100 
Nandi         
0-4 years 8/30 26.7 50 (14-384) 2/30 6.7 69 (58-80) 25/30 83.3 
5-9 years 7/35 20.0 76 (14-278) 6/35 17.1 59 (14-214) 31/35 88.6 
>10 years 5/18 27.8 26 (14-130) 5/18 27.8 56 (22-122) 18/18 100 
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NOTE.  n, number; %, percentage; EBV, Epstein-Barr Virus; PHA, 
Phytohemagglutinin. 
a Data in the table are weighted according to the 149 children who participated in all 
surveys and had interpretable Epstein-Barr Virus (EBV) specific CD8+ T-cell IFN-γ 
response. 
b Phytohemagglutinin (PHA) was used as a positive control. 
c Median EBV-specific CD8+ T-cell IFN-γ responses were calculated among children 
with positive responses and is expressed as spot forming units (SFU) per 1 x 106 
peripheral blood mononuclear cells (PBMC). 
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TABLE 5.3.  Unadjusted and adjusted prevalence ratio (PR) and 95% confidence 
interval (CI) for Pf-malaria infection and positive EBV lytic antigen CD8+ T-cell IFN-γ 
response by age group and survey period, Kenya 2002-2004 
 
 
 
 
 
 
 
 
NOTE.  Pf-malaria, Plasmodium falciparum malaria; EBV, Epstein-Barr virus; PR, 
prevalence ratio; CI, confidence interval; Ref, referent group. 
a Adjusted for sex and survey period.  Unstratified estimate for constant Pf-malaria 
compared to never infected in Kisumu (P = 0.72) and Nandi (P = 0.97) were not 
significant. Specific details on the number and prevalence of positive responses for 
each age group are included in Table 2.  
b Adjusted for sex and age group.  Unstratified estimate for constant Pf-malaria 
compared to never infected was not significant infected in Kisumu (P = 0.65) but 
significant in Nandi (P = 0.03). The number of children in Kisumu for each survey 
period was 66 and the number of children in Nandi was 83.
 Kisumu Nandi 
 
Constant Pf-malaria 
infection versus no 
infection 
Constant Pf-malaria 
infection versus no 
infection 
 PR 95% CI PR 95% CI 
Unadjusted 0.64 0.23-1.77 1.43 0.73-2.81 
Age groups a     
0-4 years 1.31 0.28-6.18 3.00 1.72-5.23 
5-9 years 0.53 0.15-1.88 1.16 0.39-3.45 
>10 years 0.78 0.16-3.53 0.98 0.33-2.95 
Survey periods b     
Baseline 1.24 0.49-3.11 1.76 1.07-2.91 
Six months 0.29 0.05-1.62 0.73 0.17-3.22 
Two years 0.21 0.05-0.92 0.22 0.02-3.23 
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TABLE 5.4.  Unadjusted and adjusted prevalence ratio (PR) and 95% confidence 
interval (CI) for Pf-malaria infection and positive EBV latent antigen CD8+ T-cell IFN-
γ response, Kenya 2002-2004 
 
 
 
 
 
 
NOTE.  Pf-malaria, Plasmodium falciparum malaria; EBV, Epstein - Barr virus; PR, 
prevalence ratio; CI, confidence interval. 
a Adjusted for sex and survey period. Unstratified estimate for constant Pf-malaria 
compared to never infected in Kisumu (P = 0.32) and Nandi (P = 0.13) were not 
significant.  Specific details on the number and prevalence of positive responses for 
each age group are included in Table 2.  
 
 
 
 
 Kisumu Nandi 
 
Constant Pf-malaria 
infection versus no 
infection 
Constant Pf-malaria 
infection versus no 
infection 
 PR 95% CI PR 95% CI 
Unadjusted 1.60 0.37-6.92 1.54 0.71-3.35 
Age groups a     
0-4 years 2.10 0.22-19.65 0.51 0.08-3.37 
5-9 years 1.14 0.26-4.99 1.47 0.58-3.63 
>10 years 2.68 0.38-18.73 1.82 0.83-3.99 
   
 
 
CHAPTER SIX: Children’s Antibody Responses to Select Malaria Antigens 
Differentially Develop and Wane by Malaria Transmission Intensity in Kenya  
  
ABSTRACT 
Background. The development of malarial antibodies that mediate protective 
immunity to Plasmodium falciparum (Pf) infection depend on malaria transmission 
intensity. However, more information is needed on the heterogeneity and kinetics of 
this multi-antigen response, particularly in areas of low malaria transmission. 
 
Methods. A cohort of 236 children aged 10 months to 15 years, living in areas of 
holoendemic (Kisumu) and hypoendemic (Nandi) Pf-malaria transmission in Kenya, 
were surveyed at baseline and six-months.  Determinants of IgG responses to five 
P. falciparum antigens (AMA-1 3D7, AMA-1 FVO, MSP-142 3D7, MSP-142 FVO, and 
LSA-1) were contrasted between the two areas. We also examined the relative 
change of antibody responses between the two surveys (six-months). 
 
Results. The proportion of positive IgG responses for all age groups was higher in 
Kisumu than Nandi; these were significant (P < .05) for AMA-1 3D7, AMA-1 FVO, 
and LSA-1 for both surveys. Antibody responses increased with age in Nandi but not 
in Kisumu. The magnitude of the decrease in the relative change in IgG responses 
to AMA-1 3D7, AMA-1 FVO and MSP-142 3D7 over a six-month period was two-fold
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greater (P < .05) among children 0-4 years old in Nandi compared to similarly aged 
children in Kisumu. Antibody responses to AMA-1 3D7, AMA-1 FVO, MSP142-3D7, 
and LSA-1 among aparasitemic children were higher (P < .05) in Kisumu than Nandi. 
There were differences (P < .05) in antibody responses by parasitemia status in 
Nandi but few in Kisumu. Males in Kisumu had higher (P < .05) antibody responses 
to AMA-1 3D7, AMA-1 FVO, MSP142-3D7, and LSA-1 than those in Nandi. All 
measured antibodies correlated strongly with one another in Nandi (P < .001) but 
few correlated in Kisumu. In general, antibodies waned over the six-month period by 
age, parasitemia status, and sex in both districts. The magnitude of the relative 
change in antibody responses was often more pronounced in Nandi than Kisumu. 
The correlation in the median relative change in antibodies responses bore similar 
patterns to those observed in other cross-sectional studies.   
 
Conclusion. Important differences in the pattern of naturally acquired immunity to P. 
falciparum exist by age, parasitemia status, and sex between areas of holoendemic 
and hypoendemic malaria transmission. These findings highlight the need to 
consider these factors when considering which antigens to target for vaccine 
development.  
 
INTRODUCTION 
Across the globe, an estimated 225 million individuals experienced malaria 
infections in 2009, resulting in an estimated 780,000 deaths 1. Efforts have been 
underway to create an effective vaccine that can further reduce the global burden of 
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malaria-related morbidity and mortality, which are greatest on the African continent 
where 78% of infections and 91% of deaths occurred, the majority in children <5 
years 1.   
Almost 50 years ago, studies of passive transfer of serum gamma-globulin 
from Plasmodium falciparum (Pf-) malaria immune adults to symptomatic children 
demonstrated that antibodies played a key role in controlling Pf-malaria infection 88-
90, 155. Yet the identification of an effective vaccine has been hindered by our limited 
understanding of how immunologic memory to Pf-malaria is developed and 
sustained in humans as well as the selection of immunogenic malaria antigens as 
vaccine candidates 82. Naturally acquired immunity to Pf-malaria does not lead to 
sterile immunity; adults residing in Pf-malaria endemic areas develop partial 
immunity that leads to asymptomatic infection in the presence of parasites. Rather, 
the critical role for antibodies appears to be their ability to establish protective 
immunity to clinical Pf-malaria infections by reducing the density of blood-stage 
parasitemia 122 after repeated exposures to Pf-malaria, thereby preventing severe 
manifestations of Pf-malaria infection (reviewed in 93). Antibodies to blood-stage 
antigens have been shown to prevent merozoites from attaching and invading red-
blood cells (reviewed in 91, 93). However, it is unclear which antibody, or combination 
of antibodies, confer protection from clinical Pf-malaria infections.  
A recent meta-analysis of population-based cohort studies found that 
individuals with IgG responses to the merozoite surface protein (MSP)-119 were at 
less risk for clinical Pf-malaria infection compared to those without IgG responses 91. 
A similar conclusion was made for the 3D7 variant of the apical membrane antigen 
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(AMA)-1 but for AMA-1 FVO, findings were inconsistent 91. However, most studies 
included in the meta-analysis were conducted in areas of stable perennial and 
seasonal malaria transmission. Malaria endemicity influences the development of 
protective immunity 11, 124 and studies examining IgG responses in hypoendemic 
(low and unstable) malaria areas are limited. One potential explanation for this 
differential pattern may be the reportedly short half-life of IgG1 responses. IgG1 
responses were reported to have a half-life of 21 days 108 but another more recent 
study of a combination of blood-stage antigens (including MSP-1 and AMA-1) 
reported IgG1 responses had a half-life of 10 days 107.  The implications would be 
that individuals infrequently exposed to Pf-malaria would not be able to sustain 
necessary antibody levels for protection from clinical Pf-malaria infection.  
To gain further insight into the transmission-intensity dependent heterogeneity 
of malaria antibody responses, we described IgG responses of children residing a 
Pf-malaria holoendemic area and contrasted them to a hypoendemic area for the 
blood-stage antigens AMA-1 3D7, AMA-1 FVO, MSP-142 3D7, and MSP-142 FVO. 
We also included the pre-erythrocytic liver stage antigen (LSA)-1.  Moreover, we 
calculated the relative change in IgG responses over a six-month period to examine 
and contrast the pattern of change between the two districts. 
 
METHODS 
Data from the Kisumu/Nandi cohort was used and has been previously described 59.  
The cohort consists of 236 children aged 10 months to 15 years from Kisumu and 
Nandi districts in western Kenya. Pf-malaria transmission in Kisumu is described as 
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holoendemic (perennial and stable) while in Nandi transmission is hypoendemic (low 
and unstable). Data were collected in July-August 2002 (baseline survey) and 
February-March 2003 (six-month follow up survey).  
Although Pf-malaria is holoendemic in Kisumu, there are relative peaks in 
transmission intensity after the long rains (March-May) and short rains (October-
December) 156. Therefore the baseline survey was conducted after the long rains 
and the six-month follow-up survey was conducted before the long rains in following 
year. Nandi experienced a classically defined malaria outbreak during the baseline 
survey and a peak in transmission six months later with an intervening period of low 
malaria incidence (C John, unpublished data).  
Equal distributions of children were enrolled by age and sex.  During the two 
face-to-face interviews, standardized forms were used to collect data and blood was 
collected for Pf-malaria parasitemia and antibody testing. Parents or guardians of 
participants provided written informed consent.  The Institutional Review Board at 
the University Hospitals of Cleveland, Case Western Reserve University (AM’s 
affiliation at the time of the study) and the Ethical Review Committee for the Kenya 
Medical Research Institute approved the original study.  The study was exempted by 
the Institutional Review Board at the University of North Carolina at Chapel Hill. 
Confirmation of Pf-malaria infection was done by microscopy of thick and thin 
blood smears. Testing for Pf-malaria antibody used the same approach as 
previously described 153. Immunoglobulin G (IgG) specific for the AMA-1 3D7, AMA-
1 FVO, MSP-142 3D7, MSP-142 FVO, and LSA-1 were detected using a bioplex 
bead-based assay. One-thousand beads of each malaria antigen were placed in 
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wells with plasma from participants and diluted to 1:5000. Included on each plate 
were negative controls (US residents with no history of malaria) and positive controls 
(pooled samples from Kisumu residents). Preparation of beads and testing were 
conducted on all samples at the same time on the same machine to reduce potential 
variation due to differences in bead preparation and assay. Although antibody 
results were calculated as mean fluorescence intensity (MFI), slight plate-to-plate 
variation led to a need to standardize results. Therefore results are expressed in 
arbitrary units (AU). For each plate, the participant’s AU values were calculated by 
dividing each participant’s MFI antibody response by the negative controls’ mean 
MFI plus three standard deviations. AU values greater than 1.0 indicated a positive 
IgG response.  
We analyzed cross-sectional data collected at baseline and six-month follow-
up stratified by district. Outcomes were dichotomous positive/negative IgG 
responses to all five Pf-malaria antigens. Exposures of interest were age group (0-4 
years, 5-9 years, and >10 years), parasitemia status (positive/negative), and sex. 
The Chi-square test and Cochran Armitage trend test were used to assess any 
significant differences among the levels of each exposure as well as to compare 
responses between the two districts. Spearman’s rank correlation coefficient was 
used to assess correlation among the different Pf-malaria malaria antibodies 
measured as continuous AU values.  
To describe the changes in Pf-malaria antibody response over time, we 
assessed the relative change in IgG response to the five Pf-malaria antigens over 
the six-month period between the two survey periods, stratified by district. However, 
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the number of children who participated in the latter survey decreased from 236 to 
210 children, representing an 11% loss to follow-up.  We did not identify any 
significant differences between the population of children who participated in the six-
month follow-up survey and those who did not. Continuous AU values were used to 
calculate the relative change in IgG response with the formula [(IgG response at 
baseline – IgG response at six-month follow-up)/IgG response at baseline]. 
Exposures included age group at baseline, parasitemia status (parasitemia at both 
survey periods, parasitemia at first survey period only, parasitemia at second survey 
period only, and never parasitemic), and sex. Levels of our exposure parasitemia 
were created based on previous findings that the presence of parasitemia was 
associated with higher levels of blood-stage antibodies 115, 116. IgG responses to the 
five Pf-malaria antigens were not normally distributed therefore we used the 
nonparametric two-sided Wilcoxon rank sum (Mann-Whitney U)/Kruskal Wallis test 
to examine any differences among the exposure levels and between districts.  The 
Exact Wilcoxon/Kruskal-Wallis test was used for small sample sizes. An extension of 
the Wilcoxon rank-sum test was used to test the trend of ordinal variables. 
Spearman’s rank correlation coefficients were calculated to assess correlation in the 
relative change between the different malaria antibodies.  All analyses were 
conducted in SAS 9.2 (Cary, NC). 
 
RESULTS 
Study participants. Of the 236 children in the cohort, interpretable results were 
available for 229 (97%) children at baseline and 207 (88%) children at six-month 
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follow-up (Table 6.1). There were no differences by age group and sex between the 
districts. A significant difference by parasitemia status was observed between 
Kisumu and Nandi children (P < .001) at both survey periods; an estimated >76% of 
children in Kisumu were parasitemic at both survey periods compared to <16% in 
Nandi. The median antibody response to all antigens except MSP-142 FVO was 
significantly higher in Kisumu compared to Nandi (Table 6.2).  
 The proportion of positive IgG responses at baseline and six-month follow-up 
was higher in Kisumu than Nandi. In general, the proportion of positive IgG 
responses was higher in Kisumu than Nandi by age group, parasitemia status, and 
sex; many of these differences reached statistical significance.   
When antibody responses were examined by age group, we found that in 
Kisumu (Figure 6.1A) there were a high proportion (>80%) of positive IgG responses 
to all Pf-malaria antigens among all age groups at baseline except MSP-142 FVO; 
yet there was an increasing trend in positive IgG response to MSP-142 FVO with 
increasing age from 60-83% (P = .045).  There remained a high proportion of 
positive IgG responses to the Pf-malaria antigens at the six-month follow-up (Figure 
6.1B) with the exception of MSP-142 FVO; responses increased from 48%-68% with 
age but this was not significant (P = .15). In contrast, the proportion of positive IgG 
responses to Pf-malaria antigens was relatively low in Nandi (<77%) compared to 
Kisumu at both survey periods. At baseline, this difference in positive responses was 
significant for all age groups for all Pf-malaria antigens except MSP-142 FVO where 
the proportion of positive responders was similar between the districts (Figures 6.1A 
and 6.1C). At six-month follow-up, significant differences by age groups between the 
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districts remained for AMA-1 3D7, AMA-1 FVO, MSP-142 3D7, and LSA-1 for all age 
groups except among the >10 year old responders to MSP-142 3D7 where 
responses were similar between districts (Figures 6.1B and 6.1D). Furthermore in 
Nandi, a trend in increasing positive IgG responses with age group was observed for 
all Pf-malaria antigens; however, this was not statistically significant (Figure 6.1C). 
At six-month follow-up this increase in IgG response with age group was statistically 
significant for all Pf-malaria antigens except LSA-1 (Figure 6.1D). Taken together, 
these results indicate the proportion of positive IgG responses among all age groups 
is higher in Kisumu relative to Nandi for all antigens except MSP-142 FVO; however, 
age trends with IgG responses were primarily detected in Nandi and not Kisumu.  
 In our assessment of parasitemia status and antibody response, we found 
that IgG responses to AMA-1 3D7, AMA-1 FVO, and MSP-142 FVO did not differ by 
parasitemia status at baseline or six-month follow-up in Kisumu; however, significant 
differences were noted for LSA-1 at both survey periods and MSP-142 3D7 at six-
month follow-up (Figures 6.2A and 6.2B).  In Nandi, however, significant differences 
in IgG responses to all Pf-malaria antigens by parasitemia status were observed at 
baseline. Differences in Nandi were also observed at six-month follow-up for AMA-1 
3D7, AMA-1 FVO, and LSA-1. When the districts were contrasted, we observed 
similar proportions of positive IgG responses among parasitemic children at baseline 
and six-month follow-up (except for AMA-1 3D7 and AMA-1 FVO during the latter 
survey). However, aparasitemic children in Kisumu had elevated proportions of 
positive IgG responses than aparasitemic children in Nandi at both survey periods 
for all antigens except MSP142-FVO (Figures 6.2A and 6.2B). This would suggest 
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that aparasitemic children in Kisumu were able to maintain antibodies to pre-
erythrocytic and blood-stage antigens in the absence of stimulation from parasites. 
Meanwhile, children who were parasitemic were able to elicit an immune response 
regardless of their residence.        
 There were no differences in IgG responses between males and females in 
either district, during either survey (data not shown). Yet at baseline, males and 
females in Kisumu had a significantly higher proportion (P < .05) of positive 
responses when compared to their counterparts in Nandi to AMA-1 3D7 (>97% vs 
<64%), AMA-1 FVO (>95% vs <68%), MSP-142 3D7 (>95% vs <66%), and LSA-1 
(>90% vs <56%). This significant difference was also present at six-month follow-up, 
where higher IgG responses to MSP-142 FVO was found among females in Kisumu 
compared to Nandi (71% vs 46%). Adjusting for parasitemia status accounted for 
differences between females but significant differences remained among males.  
Correlations between antibodies differed by malaria endemicity. Examination of 
the correlation between antibodies highlighted a few interesting observations (Tables 
6.3A-6.3D). In Kisumu, correlations between allelic variants of the same antigen 
(AMA-1 3D7 and AMA-1 FVO; MSP-142 3D7 and MSP-142 FVO) were high 
(Spearman’s rho range: 0.755-0.953) at both survey periods (Tables 6.3A and 6.3B). 
Furthermore, there were relatively strong correlations (Spearman’s rho range: 0.490 
- 0.575) between LSA-1 and MSP-142 antigens at both survey periods. At six-month 
follow-up, antibodies to LSA-1 were also slightly correlated to the AMA-1 antigens 
(Spearman’s rho range: 0.268 - 0.284) but not at baseline. There was slight 
correlation between AMA-1 FVO and MSP-142 3D7 (Spearman’s rho: 0.226) at 
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baseline but this was not observed at six-month follow-up. However, in Nandi, there 
were significantly strong correlations between all the antibodies (Spearman’s rho 
range: 0.563-0.967) (Tables 6.3C and 6.3D). The pattern of correlation among 
antibodies suggest that in holoendemic areas such as Kisumu, specific antibodies 
are produced in response to Pf-malaria infection while in hypoendemic area such as 
Nandi, a broad array of antibodies are produced.   
The relative change in antibody responses to malaria antigens suggests 
waning of antibodies over time. Overall, the median relative change in antibody 
response for all antigens decreased over the six-month period in Kisumu and Nandi 
by age group, parasitemia status, and sex (Tables 6.4 and 6.5). This suggests that 
antibody responses wane over time and therefore a proportion of antibodies are 
inferred to be short-lived, even in holoendemic areas. 
In Kisumu, there were no significant differences in the median relative change 
by age group for any of the Pf-malaria antigens (Table 6.4). In addition, there was no 
observed trend in the relative change of antibody responses with age group. In 
Nandi, there were no differences among the age groups; however, there was a 
pattern observed for all antigens (except MSP-142 3D7) in which the magnitude of 
the relative change became smaller with increasing age (Table 6.5). Hence the 
children in the youngest age groups experienced the largest decline in antibody 
responses compared to children in older age groups. When the median relative 
change in antibody responses was compared between the districts, the magnitude of 
the decrease in antibody response was larger in Nandi (40-52%) compared to 
Kisumu (12-22%). These 2-3 fold differences were significant for AMA-1 3D7, AMA-
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1 FVO, and MSP-142 3D7 among children 0-4 years of age and AMA-1 FVO, and 
MSP-142 FVO among children 5-9 years old (Tables 6.4 and 6.5).  
 We observed a number of intriguing patterns in the relative change of 
antibody responses in relation to parasitemia status. There was a significant 
difference in the median relative change in antibody responses to MSP-142 3D7 by 
parasitemia status in Kisumu (Table 6.4); however, there were no significant findings 
in Nandi (Table 6.5). As previously noted, the median relative change in antibody 
responses over the six-month period decreased regardless of parasitemia status; 
however, the degree of the median relative change in antibody response varied by 
parasitemia status and district (Tables 6.4 and 6.5). In Kisumu, the largest median 
relative change was among children who were aparasitemic at both survey periods, 
ranging from 38% (MSP-142 3D7) to 69% (LSA-1). This indicates that in holoendemic 
areas, the lack of immune stimulation from infection results in a substantial loss of 
antibodies compared to those infected at least once during the surveys. In Nandi, 
the pattern is not as clear. The greatest decrease in the median relative change in 
antibody responses to MSP-142 3D7 (60%), MSP-142 FVO (48%), and LSA-1 (59%) 
were among children who were parasitemic at baseline only. These results are 
plausible because we would expect children with limited exposure to Pf-malaria 
infection to have a sudden increase in antibody responses while parasitemic, 
resulting in a sizable decrease once parasitemia was cleared. However, for AMA-1 
3D7, the largest change (40%) was among children who were parasitemic at six-
month follow-up only while for AMA-1 FVO (42%) it was among children who were 
aparasitemic at both survey periods. The finding for AMA-1 3D7 is counterintuitive 
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because we would expect the largest increase in the median relative change to be 
among those who later became parasitemic, not the largest decrease. Meanwhile, 
the finding for AMA-1 FVO is less puzzling but still unexpected. We did not expect 
children in Nandi who were aparasitemic at both survey periods to have elevated 
antibody levels. However, a closer examination of aparasitemic children showed that 
the median relative change in antibody responses to all antigens ranged from a 33-
45% decrease, once again suggesting that antibodies wane without parasite 
stimulation. As for the smallest amount of median relative change in antibody 
responses, patterns were similar in Kisumu and Nandi. Children parasitemic at both 
survey periods had the smallest median relative change for AMA-1 3D7 and AMA-1 
FVO whereas the smallest median relative change for MSP-142 3D7, MSP-142 FVO 
and LSA-1 were among children who were parasitemic only at six-month follow-up. 
Both of these findings are feasible because we would expect few changes in 
antibody responses in children who were parasitemic at both survey periods, or 
whose antibody responses would have increased as a result of parasitemia during 
the latter survey.  
 We also noted interesting patterns in parasitemia status when we drew 
comparisons between Kisumu and Nandi (Tables 6.4 and 6.5). First, among children 
who were parasitemic at both survey periods, the magnitude of the median relative 
change was greater in Kisumu than Nandi for all antigens except MSP-142 FVO. This 
pattern of a greater magnitude in median relative change in Kisumu compared to 
Nandi was also observed among children who were aparasitemic at both survey 
periods. Both observations suggest that antibody responses wane more so in 
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Kisumu than Nandi and are inconsistent with the idea that children in holoendemic 
areas should have less of a decline in antibody responses over time than those in 
hypoendemic areas. However, upon further examination, there were few children 
(n=5) in Nandi who were parasitemic and few children (n=6) in Kisumu who were 
aparasitemic at both survey periods.  Data from these limited observations could 
explain the inconsistency between our expectations and our results. Second, the 
magnitude in the median relative change was greater in Nandi than Kisumu among 
children who were parasitemic only at baseline. This is in accordance with our 
expectation that children repeatedly infected with Pf-malaria would be able to 
maintain antibodies better than children with limited exposure. Finally, among 
children who were parasitemic only at six-month follow-up, the magnitude of the 
median relative change was once again greater in Nandi than Kisumu. Likewise this 
observation is plausible because children repeatedly infected with Pf-malaria should 
theoretically have antibody levels greater than children rarely infected.  
 In general, the median relative change in antibody response was greater in 
females than males in Kisumu but these were not significant (Table 6.4). Males in 
Nandi had higher median relative change in antibody responses than females but 
this also did not reach statistical significance (Table 6.5). Significant differences in 
the median relative change were identified between males in Kisumu and Nandi for 
AMA-1 3D7, AMA-1 FVO, and MSP-142 FVO whereas only a significant difference 
among females between the two districts was noted for AMA-1 FVO.  Once again, 
these differences are linked to heterogeneity of malaria transmission intensities at 
the districts.  
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Antibodies do not decrease independently of one another over time. We 
detected significant correlations in the relative change in antibody responses to all 
antigens in Kisumu and Nandi (Table 6.6) and these correlations mimicked patterns 
previously observed in the cross-sectional analyses. In Kisumu, the strongest 
correlations were between genotypes of the same antigen (Spearman’s rho range: 
0.816-0.914) while moderately strong correlations were observed between LSA-1 
and the MSP-142 genotypes (Spearman’s rho range: 0.623-0.682). The correlations 
between the AMA-1 genotypes to MSP-142 genotypes and LSA-1 genotypes were 
modestly correlated (Spearman’s rho range: 0.374-0.387) whereas in the cross-
sectional analyses, these were not correlated. Once again in Nandi, all relative 
changes in antibody responses were strongly correlated to one another (Spearman’s 
rho range: 0.504-0.927) whereas the correlation between MSP-142 3D7 and LSA-1 
(Spearman’s rho: 0.289) was modestly correlated, but still significant. These findings 
suggest that antibody responses do not decrease independently of one another but 
rather, there is a general waning of antibody responses over time, the pattern of 
which varies with the transmission intensity of the location. 
 
DISCUSSION 
As expected, we observed a higher proportion of positive IgG responses to select 
Pf-malaria antigens by age, parasitemia status, and sex in a Pf-malaria holoendemic 
area compared to a hypoendemic area. We also detected significant differences in 
the median relative change in antibody responses over a six-month period by age 
group and sex between the districts; intriguing patterns were observed between 
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districts in the relative change in antibody responses by parasitemia status. Within 
each district, however, there were few differences by age and parasitemia status in 
Kisumu whereas a number of important differences were detected in Nandi; there 
were no observed differences by sex in either district. We also did not observe any 
differences in the median relative change in antibody responses over six-months 
within each district by age, parasitemia status, or sex.  
Our findings of positive IgG response in relation to age group between the 
districts highlight the disparate immunological experiences of children living in Pf-
malaria holoendemic areas compared to hypoendemic areas. Children in areas like 
Kisumu experience repeated Pf-malaria infections shortly after birth, building a 
repertoire of antibodies that help them develop immunity to clinical malaria infection 
by 2-3 years and decreased parasite density between ages 10-14 122. However, the 
development of antibody responses is delayed in areas such as Nandi where 
children and adults of all ages are still susceptible to clinical malaria infection 10, 124, 
157. Hence it is not surprising that we detected significant differences in the 
proportion of positive IgG responses to the blood-stage antigens between the two 
districts. We only detected a few patterns of increasing antibody response (MSP-142 
FVO and LSA-1) with age in Kisumu, although not always significant. The lack of an 
age trend among AMA-1 responders is not unexpected as AMA-1 (3D7 and FVO) is 
highly immunogenic 94, as evidenced by the near saturation of responses among all 
age groups at both time points. Furthermore, young children often have the highest 
levels of parasites, which are associated with elevated antibody responses. Yet what 
is of interest is the apparent age trend observed in Nandi, which we would have 
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expected in Kisumu. Of interest is that Nandi experienced a classically defined 
malaria outbreak during the first survey and a peak in transmission during the 
second survey. Thus the pattern we observed in Nandi likely exemplifies the age 
trend often used to characterize the development of immunity in stable areas of 
malaria transmission. Furthermore, the magnitude of the median relative change 
differed between the two districts by age groups. Although antibodies appeared to 
wane over time in both districts, the magnitude of the median relative change in IgG 
response to AMA-1 3D7, AMA-1 FVO, and MSP-142 3D7 among Nandi children 
aged 0-4 years was a 2-3 fold difference compared to similarly aged children in 
Kisumu (P < .05). Furthermore, there was a general pattern in Nandi in which the 
magnitude of the relative change decreased from the youngest age group to the 
oldest age group. Once again, this reinforces the theory that young children in 
hypoendemic malaria transmission areas have lower antibody levels than children in 
holoendemic areas. Our findings of a lack of trend in Kisumu between age group 
and antibody response reiterates Drakeley’s caution that using age-specific 
seroprevalence data to estimate malaria transmission intensities are highly 
dependent on the immunogenicity of antigens that are used as well as the 
geographic variability of the parasitic strain 94.  
 There was a striking difference in IgG responses for AMA-1 3D7, AMA-1 
FVO, MSP-142 3D7, and LSA-1 between the districts among aparasitemic children.  
Antibodies to MSP-1 and AMA-1 are reportedly short-lived 107, therefore we would 
not expect to see high levels of positive IgG responses in aparasitemic individuals. 
However, immunity in those repeatedly infected with Pf-malaria reflects past and 
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present infections. Therefore we would hypothesize that antibodies to Pf-malaria 
infection would be produced from a combination of short-lived plasma cells (SLPC) 
and long-lived plasma cells (LLPC), of which LLPCs would accumulate over time in 
individuals repeatedly infected with Pf-malaria 111. This is further supported by our 
observation of the magnitude of the relative change in antibody response by 
parasitemia status. Although there was a general waning of antibody responses over 
time suggesting that SLPCs comprise a substantial proportion of antibodies, the 
magnitude of the median relative change in antibody responses was smaller in 
Kisumu compared to Nandi among children parasitemic only at baseline or six-
month follow-up. This suggests that LLPCs persist in Kisumu children whereas the 
increase in antibodies in Nandi children was due to SLPCs. However, we are 
cautious in our interpretations because parasitemia status and antibody responses 
were measured at the same time. Antibodies can persist after parasite clearance 
hence children who were aparasitemic but had elevated antibody responses may 
have cleared parasites shortly before the surveys, particularly in children living in 
Kisumu. Future studies that are able to accurately assess the temporal relationship 
between parasitemia and antibody response should be conducted to corroborate our 
findings. 
 The differences in positive IgG responses detected by sex between Kisumu 
and Nandi were unexpected. Heterogeneity in bednet usage could not explain this 
phenomenon because only 4% of participants in Kisumu and <1% in Nandi reported 
using bednets at the time the surveys were conducted0. After adjusting for 
parasitemia status, there was still a significant difference among males between the 
   
 105
districts. We can only conclude that there must be other factors unmeasured in our 
study that differed between the two groups. 
 Our observed patterns of correlation in antibody responses in the districts 
were consistent with another study in this area 101. In Nandi there was strong 
correlation between all the antibodies suggesting that children periodically infected 
with malaria can elicit an immune response to a repertoire of antibodies. However in 
Kisumu, strong correlation in responses was only observed between the different 
AMA-1 genotypes, MSP-1 genotypes, and MSP-1 genotypes to LSA-1. The lack of 
evidence for correlation among the other antibodies (for example, AMA-1 3D7 and 
MSP-1 3D7) may be due to the high proportion of positive antibody responses, 
which provides limited statistical ability to detect significant correlations. This 
observation should serve as a cautionary note to researchers trying to identify 
immunological determinants of protection. Strong correlation among antibodies in 
hypoendemic Pf-malaria areas does not equate to protective immunity nor does 
limited correlation among antibody responses indicate the absence of protective 
immunity in holoendemic Pf-malaria areas. Future studies should examine 
correlations among additional pre-erythrocytic and blood stage-antigens as well as 
study areas with varying Pf-malaria transmission intensities to further explore this 
intriguing paradox.   
There are limitations with our study. Like other studies of malaria antibody 
response, we are unable to address whether differences in IgG responses between 
the districts, or relative changes in antibody levels within an individual, reflect 
functional modifications in immune response. We may have also encountered 
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situations in which children were no longer parasitemic at the time of the survey but 
their antibody responses were still elevated. This was likely to occur predominantly 
in Kisumu where children experience numerous infections. However, we were able 
to detect parasitemia in >76% of Kisumu children at both surveys. Therefore this 
issue was likely to be minimal and did not affect our findings. Furthermore, although 
the use of AUs provides a means to standardize results within a study, AU values 
are not directly comparable across different studies. Hence we could only draw 
comparisons about directionality of findings. Another limitation is the nature of the 
relative change calculation and interpretation. A 200% increase may indicate change 
in IgG response from 0.2 AU to 0.6 AU yet this child remains a negative IgG 
responder. Finally, due to the limited power of our study, we were unable to examine 
more complex relationships in our analyses. For example, our analysis of 
parasitemia and relative change in antibodies levels over time was limited by the 
number of children who were aparasitemic at both survey periods in Kisumu (n=6) 
and parasitemic at both survey periods in Nandi (n=5). As a result, we did not have 
power to detect small yet important differences by parasitemia status. 
Our study findings are generally consistent with previous studies of IgG 
responses in relation to malaria transmission intensity. We found a higher proportion 
of antibody responders with increasing malaria transmission intensity 94, 95, 101. We 
detected significant differences in IgG responses by age group between the two 
districts and similar age trends within the districts 95, 101. We also noted the saturation 
of AMA-1 (3D7, FVO) IgG responses across all age groups in Kisumu but not Nandi 
94.  The increase in the proportion of antibody responses with age in Nandi may have 
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been due to the Pf-malaria infections from an on-ongoing outbreak yet our findings 
are similar to other studies in low malaria transmission areas where an age trend for 
AMA-1 and MSP-1 antigens was observed 94, 95, 101. Patterns of correlation between 
antibody responses were consistent with a previous study by Noland and 
colleagues, including MSP-1 antibody patterns despite the use of different target 
antigens (MSP-142 in this study, MSP-119 in the other study) 101.  However, 
correlations differed from another study by Chelimo and colleagues that found a 
strong correlation between AMA-1 and MSP-1 antibodies, as well as a weak but 
significant correlation between LSA-1 and AMA-1 antibodies 119. However the study 
led by Chelimo was conducted among infants and young children who have 
immunological capacities different from older children. We detected a difference in 
LSA-1 responses by parasitemia status in the malaria holoendemic area unlike 
Noland’s study, despite both studies having been conducted in the same study area 
though during different time periods 101. Differences may be attributed to assay and 
the use of AUs which varied between the studies. Our detection in an area of low 
malaria transmission of differences in IgG responses to AMA-1 and LSA-1 by 
parasite status was consistent with a study by Bull and colleagues that found similar 
differences during a low malaria-transmission season 115.  However, John and 
colleagues did not detect differences in LSA-1 antibody responses by parasitemia 
status 118. Finally, our findings that antibodies wane over time regardless of malaria 
transmission intensity are also consistent with previous studies 100, 107. 
Our findings reveal important differences in antibody responses between areas of 
high and low malaria transmission that could be used to inform future research on 
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immunological markers of Pf-malaria protective immunity and vaccine development. 
First, we did not observe an age-trend in antibody responses in Kisumu because the 
proportion of positive responders in all groups was >83%, except to MSP-142 FVO. 
This suggests that children <5 years of age are able to mount an immune response 
similar to older children. Could these two antigens induce an immune response that 
protects from clinical Pf-malaria infections? Studies of clinical Pf-malaria infections 
have often examined antigens independently. However it is likely that a multivalent 
vaccine will be necessary therefore longitudinal studies that examine multiple 
antibody responses in unison are needed.  Furthermore, we identified that antibody 
responses waned over time, regardless of the malaria transmission intensity. 
However, the magnitude of change varied by antigens and was more pronounced 
among young children in the hypoendemic area. Many questions remain about B-
cell memory to the array of Pf-malaria antigens. Are SLPCs the predominant source 
of antibodies in children infrequently infected with Pf-malaria, or only in young 
children? Does the loss in response represent a functional loss in immune 
response? Are the half-lives of IgG1 antibodies the same for all Pf-malaria antigens? 
There is a clear need for further research into the heterogeneity in function and 
longevity of Pf-malaria specific antibodies. Finally, as we pointed out earlier, patterns 
of antibody correlations differed between areas of holoendemic and hypoendemic 
malaria transmission. Caution should be taken when making interpretations because 
strong correlations among antibodies do not necessarily indicate protective 
immunity. Likewise, limited correlation among antibodies does not suggest the 
absence of protective immunity. 
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CONCLUSION 
This study identified disparities in the proportion of positive IgG responses to 
select Pf-malaria antigens between a holoendemic and hypoendemic area of Pf-
malaria transmission by age, parasitemia status, and sex. An overall waning of 
antibody responses was observed over six-months by age and parasitemia status; 
however, differences between the study populations in the magnitude of median 
relative change in antibody response by age was detected.  These findings highlight 
the important differences in naturally acquired immunity between areas of disparate 
malaria transmission intensities and have important implications when assessing the 
effectiveness of vaccines across populations.    
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FIGURE 6.1. Proportion of IgG positive malaria antibody responses ( >1  arbitrary units) by age group at baseline and six-
month follow-up in Kisumu (A and B) and Nandi (C and D) in Kenya, 2002-2003. P-values in the graph represent the 
Cochran-Armitage Trend Test for differences in the proportion of positive antibody responses among age groups within a 
district. Asterisks represent statistically significant differences (P < .01) in the proportion of positive antibody responses 
between districts within the same age group. Bar represent error bars. At baseline, the number of children who were 0-4 
years, 5-9 years, and >10 years in Kisumu was 35, 39, and 30, respectively while in Nandi, it was 42, 45, and 38, 
respectively. At the six-month follow-up, the number of children who were 0-4 years, 5-9 years, and >10 years in Kisumu 
was 21, 36, and 34, respectively and in Nandi, it was 29, 47, and 40, respectively. 
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TABLE 6.1. Summary of participants in the Kisumu/Nandi Cohort, Kenya 2002-2003 
 Baseline Six-month Follow-up 
 District District 
 Kisumu 
(holoendemic)
Nandi 
(hypoendemic)
Kisumu 
(holoendemic) 
Nandi 
(hypoendemic)
 n % n % n % n % 
Sex         
Male 61 58.7 61 48.8 53 58.2 59 50.9 
Female 43 41.3 64 51.2 38 41.8 57 49.1 
Age group (in years)        
0-4 35 33.7 43 33.6 21 23.1 29 25.0 
5-9 39 37.5 45 36.0 36 39.6 47 40.5 
>10 30 28.9 38 30.4 34 37.4 40 34.5 
Parasitemia 
status 
        
Parasitemic 80 76.9 20 16.0 72 79.1 14 12.1 
Aparasitemic 24 23.1 105 84.0 19 20.9 102 87.9 
Total 104  125  91  116  
 
NOTE.  n, number; %, percentage 
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TABLE 6.2. Median antibody responses for select malaria antigens at baseline by 
district, Kenya 2002  
 Kisumu Nandi  
 Median Range Median Range P-value*
AMA-1 3D7 4.53 0.17-7.24 2.04 0.05-7.68 <.001
AMA-1 FVO 4.57 0.16-6.77 2.18 0.04-10.83 <.001
MSP-1 3D7 5.19 0.22-12.66 3.14 0.05-15.37 .008
MSP-1 FVO 2.33 0.11-6.96 2.12 0.03-12.37 .63
LSA-1 3.71 0.39-10.88 0.99 0.18-9.17 <.001
 
*P-values in table represent the Wilcoxon-Mann-Whitney U Test for differences in 
median antibody responses between Kisumu and Nandi. The number of participants 
in Kisumu and Nandi was 104 and 125, respectively. Antibody responses are 
measured in arbitrary units. See methods for explanation of arbitrary units 
calculation.  
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CHAPTER SEVEN: DISCUSSION 
 
It has been over 50 years since Burkitt first published his description of eBL20 and 
Cohen and McGregor demonstrated the protective effect of gamma-globulins.88, 90 In 
the years since these important milestones in the history of Pf-malaria infection, 
advances have been made in our understanding the pathogenesis but there is still 
more work to be done to further reduce the global burden of diseases that are 
directly, and in-directly, attributable to Pf-malaria infection.  
  
Summary of Findings 
We have described a number of important findings in this dissertation that should 
guide future research on cumulative effect of Pf-malaria infections on EBV 
persistence and potential immunological markers of Pf-malaria immunity to 
symptomatic illness. In our first specific aim, we found that repeated Pf-malaria 
infections were associated with a loss in CD8+ T-cell production of IFN-γ against 
EBV lytic antigens but not latent antigens. This loss in CD8+ T-cell functionality was 
most pronounced among the age group in which eBL has been commonly reported. 
The loss of immunological control over EBV lytic replication may lead to more EBV 
latently infected B-lymphocytes thereby increasing the risk for developing eBL. 
 In our second specific aim, we found that antibody responses, and the 
proportion of positive responders, were higher in a malaria holoendemic areas when
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compared to a hypoendemic area. Although antibody responses have been reported 
to increase with age in holoendemic areas, we observed a high proportion of positive 
responders across all age groups because even the youngest children had already 
experienced repeated Pf-malaria infections to have accumulated antibody 
responses. Interestingly, we did observe an age trend in the hypoendemic area, 
where they were experiencing an outbreak. We also found that antibody responses 
waned over time regardless of the malaria transmission intensities.  However, the 
greatest magnitude of change was among children <5 years old in the hypoendemic 
area whereas it varied in the holoendemic area. These findings support the 
differential acquisition of antibodies to Pf-malaria infections by malaria transmission 
intensity and age.      
 
Public Health Significance and Future Directions 
Specific Aim 1: Findings suggest that children repeatedly exposed to Pf-malaria 
infections lose immunological control over latent EBV infection. Specifically, the 
ability of their CD8+ T-cell to produce IFN-γ to lytic antigens has diminished leading 
to reactivation of lytic replication.  Longitudinal studies that can accurately measure 
EBV CD8+ T-cells IFN-γ  and Pf-malaria infections are needed to corroborate our 
findings.  
What is interesting about the finding of reduced EBV lytic antigen CD8+ T-
cells response is that it coincides with the time frame in which children are beginning 
to develop protection from symptomatic illnesses to Pf-malaria infections and are 
able to better control parasite density. Therefore as immunity to Pf-malaria develops, 
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so does the risk for eBL. Though this is circumstantial evidence, it points to a critical 
time frame that should be further investigated as these two events are unlikely to be 
occurring independently of one another. Immune responses are a combination of 
innate, cellular, and humoral responses that work in unison to control infection, 
including multiple infections. Hence a more comprehensive approach should be 
considered when researching the interaction between Pf-malaria and EBV co-
infection. It is understandable to reduce complex systems into simplified 
relationships and important information can be gleaned from studies like ours where 
we investigated one aspect of the immunologic response. Yet research should strive 
to build upon these simplified relationships to obtain a more accurate understanding 
of how the immune system orchestrates responses to Pf-malaria and EBV during co-
infection. Furthermore, future research should be conducted to ascertain whether 
our observed decrease in CD8+ lytic antigen T-cell IFN-γ response among 5-9 year 
olds in a holoendemic malaria area contributes to the development eBL. Due to the 
difficulties in conducting a cohort study with eBL as an outcome, novel approaches 
will need to be considered.  
Finally, our analysis examined the cumulative effect of Pf-malaria infections 
on latent EBV infection at the individual-level. The use of a surrogate for Pf-malaria 
infection at the district-level has been informative but does not, and cannot, take into 
account differences in individual-level risks for the if we are to This is a crucial step if 
we are to decipher the immunological relationship between Pf-malaria and EBV co-
infections. Efforts should be made to build upon our attempt, using data from a 
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longitudinal study with shorter follow-up intervals so an accurate measure of 
cumulative Pf-malaria can be made.  
 
Specific Aim 2: Our results highlight important differences in antibody responses to 
Pf-malaria antigens among children living in areas with different malaria 
transmission intensities. The lack of an age trend in the high malaria transmission 
area to select blood-stage antigens was due to a high proportion of positive 
responders in each age group. This suggests that the immune system of young 
children can mount an immune response similar to older children. More importantly, 
the lack of an age-trend for a number of antigens emphasizes that antibodies work in 
unison to eliminate an infection. Studies have typically examined antibodies 
independently of one another but it is unlikely a vaccine will target one antigen for a 
complex organism such as Plasmodium falciparum. To facilitate the development of 
a multivalent vaccine, it is important for research to begin focusing on how multiple 
antibody responses work together to overcome infection and illness.    
Furthermore, we detected a decline in antibody responses over time, 
regardless of the malaria transmission intensity. But the magnitude of change was 
not the same for all antigens and was more pronounced for the youngest age group 
in the malaria low transmission area. This observation raises numerous questions. 
Are SLPCs responsible for fighting infection in children infrequently infected with Pf-
malaria? Does the loss of antibody response represent a functional loss in 
immunity? Are the half-lives of IgG1 antibodies the same for all Pf-malaria antigens? 
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There is a clear need for further research into the function and longevity of 
antibodies to Pf-malaria.  
 
Conclusion 
The quest for an effective vaccine against Pf-malaria infections offers great 
hope for the future but we are still years, even decades away from developing a 
vaccine for use. Furthermore it is likely that the first generation of vaccine will be 
designed to protect from symptomatic and severe illness rather than infection. 
Although protection from symptomatic illness is vital, it may still leave children 
vulnerable to eBL. Therefore, we must continue in our pursuits to understand the 
multi-faceted pathogen that is Pf-malaria to gain knowledge on its natural history and 
interaction with other pathogens to aid in identifying novel approaches and strategies 
to reduce its impact on the lives of infants, children, and adults around the world.  
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APPENDIX A: CWRU/KEMRI Blood Sample Collection and Questionnaire Form 
1 
 
Study Title: Immunologic Studies of Endemic Burkitt’s Lymphoma 
Sample collection form 1: Blood sample collection for investigational studies 
 
 
Patient study number (STID)  __ - __ - __ __ __ __ - __ __ - BL - __   
                                      (site) (village)   (household)    (individual)          (round) 
 
Date of sample collection __ __/ __ __ / __ __ (dd/mm/yy) 
 
First name __________________________________________ 
 
Middle name ________________________________________ 
 
Last name ___________________________________________ 
 
Date of birth __ __/ __ __ / __ __ (dd/mm/yy) 
 
Sex        male (1)       female (2) 
 
Has this child taken any anti-malarial medication for malaria within the past 2 weeks?
                          
                    Yes (1)       No (2) 
 
If yes, which medication _______________________________________________ 
 
Has the child taken any traditional medicines? 
         
                    Yes (1)       No (2) 
 
If yes, which one(s) ____________________________________________________ 
 
Does this child sleep under a bed net?          Yes (1)  No (2) 
 
If yes, is this net treated?                 
             Yes (1)  No (2) 
Has the house this child sleeps in been sprayed with insecticide by the Ministry of 
Health? 
                    
       Yes (1)        No (2) 
 
Ethnic group _____________________________    code 
 
List Samples collected: 
? Blood smear  ____________________(yes or no) 
? Hemoglobin  ____________________(gm/dl) 
? Purple top (~ 500 μl)  _____________(yes or no) 
? Green top (2-5 ml) _______________(indicate amount taken) 
? Other ___________________________(specify type of specimen) 
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APPENDIX B: Calculation of Inverse Probability Weights 
 
An assumption when using generalized estimating equations (GEE) is that missing 
data, or observations, are missing completely at random); missingness of data is 
independent of observed and unobserved data 158. When data do not appear to 
satisfy this assumption, a less restrictive assumption on the missingness of data is 
needed. 
 Inverse probability weights (IPWs) are one method that can be used to 
address missing data, or observations, and is less restrictive about the missingness 
of data than GEE.  When using IPW, observations are assumed to be missing at 
random; missing data are dependent on observed data but independent of 
unobserved data. 158  To calculate IPWs, the probability of participation is modeled 
using available predictor variables.  The inverse of the predicted probabilities are 
calculated and assigned to each individual with complete data.  Individuals with 
complete data are weighted to represent individuals with similar characteristics who 
have missing data. 
 To calculate the predicted probabilities for our study, we used logistic 
regression with first order interaction terms using the following equation: 
Log[pi/1-pi]= b0, + b1(sex) + b2(age group 0-4 years) + b3(age group 5-9 
years) + b4(site of residence) + b5(sex*age group 0-4 years) + b6(sex*age 
group 5-9 years) + b7(sex*site of residence) + b8(age group 0-4 years*site of 
residence) + b9(age group 5-9 years*site of residence). 
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Where pi is the probability of child i (i =1,2,3…n) participating in all surveys.  Taking 
the inverse of the predicted probabilities, the mean IPW was 1.44 and ranged from 
1.14-1.92.  Children who participated in all three surveys were assigned the mean 
IPW value whereas children with missing observations were assigned an IPW of 0. 
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